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bp 
Breakpoint cluster region Abelson 
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CEBPA 
CGI 
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CCAAT/enhancer-binding protein α 
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CR 
Ct 
(Cytogenetically normal) acute myeloid 
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Complete remission 
Cycle threshold 
dHPLC Denaturing high performance liquid 
chromatography 
DMSO 
DNMT 
EFS 
Dimethyl sulfoxide 
DNA methyltransferase 
Event free survival 
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FLT3 FMS-like tyrosine kinase receptor-3 
FISH Fluorescence In-Situ Hybridisation 
HRM High Resolution Melting Analysis 
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IDH1 Isocitrate dehydrogenase 1 
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MGB 
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MPN 
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Overall survival 
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(Quantitative) polymerase chain reaction 
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PML-RARA 
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PML-Retinoic Acid Receptor α mutations 
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R Arginine 
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I. Introduction 
1.1 Acute myeloid leukaemia: 
Acute myeloid leukaemia is a heterogeneous malignancy with clonal proliferation of 
haematopoietic precursor cells infiltrating in blood, bone marrow and other tissues. It 
represents the most common form of acute leukaemia in adults and occurs increasingly 
frequently with age. The median onset of AML is 65 years resulting in an incidence of 16.8 
per 100,000 for individuals older than 65 years and 1.8 in those younger than 65 years 
(Howlader N, 2013; Hoffbrand AV & Moss PAH, 2011). More than 18,000 cases of AML 
are diagnosed annually in Europe with a five year relative survival rate of 19% (Visser O, et 
al. 2012). 
Within the process of haemopoiesis, leukaemic transformation is considered to take place at 
the stage of the haematopoietic stem cell or early progenitor cell that has already started to 
differentiate. These immature cells are assumed to gain specific survival advantages by at 
least two mechanisms: Alteration of genes that affect proliferation known as class 1 genes, e. 
g. internal tandem duplications or tyrosine kinase domain mutations of the FMS-like tyrosine 
kinase 3 (FLT3-ITD or -TKD mutations), mutations of the neuroblastoma RAS viral 
oncogene (NRAS mutations), mutations in the Janus Kinase 2 (JAK2), cKIT mutations etc. 
and modification of those that affect differentiation classically named class 2 genes, e. g. 
mutations in the nucleophosmin gene (NPM1 mutations), PML-Retinoic Acid Receptor α 
mutations (PML-RARA), CCAAT/enhancer-binding protein α (CEBPA-mutations), Runt-
related transcription factor 1 (RUNX1 mutations), as illustrated in Figure 1. However, 
recently it has been shown that this theory needs to be expanded as not all of the patients with 
AML carry mutations in class 1 or 2 genes (Shen Y et al., 2011; Shih A et al., 2012; Thiede C, 
2012). Whole genome and exome sequencing studies have revealed that somatic mutations in 
epigenetic regulators are a frequent occurrence in AML and contribute to malignant 
transformation (Ding L et al. 2012; Schoofs T & Mueller-Tidow C, 2011). One of the most 
common mutations is located in the de novo methyltransferase 3A (DNMT3A) gene 
regulating DNA methylation.  
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Figure 1: Mutations contributing to the pathogenesis of AML (Reproduced from Thiede C, 
2012) 
 
1.2 Prognostic marker in AML: 
Conventionally, AML cases were classified into three risk groups (favourable, intermediate 
and adverse) by morphologic features, flow cytometric examination and cytogenetic 
fluorescence in situ hybridisation (FISH) analysis but recently recurrent genetic alterations 
have been taken into consideration and were incorporated into the WHO classification of 
acute myeloid leukaemia (Vardiman JW et al., 2009; Godley LA, 2012).  
In general, patients with AML with a favourable risk classification receive conventional 
chemotherapy whereas patients with an unfavourable risk classification are chosen for 
allogeneic haematopoietic stem cell transplantation (HSCT) (Martelli MP et al., 2013). 
However, the prognostic group encompassing most of the adult AML patients (40-50% of all 
AML cases) is cytogenetically normal AML (CN-AML), part of the intermediate risk group 
(Lin TL & Smith BD, 2011). Patients out of this risk group are difficult to assign to different 
treatment options because of the high variance of molecular subtypes and their highly 
differing treatment outcomes.  
The prognostic importance of further risk sub classifications of the large and heterogeneic 
diverse CN-AML group by mutational analysis was shown by many studies examining the 
outcome of genes that are frequently associated with leukaemia. It was shown that genetic 
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predictors, among them DNMT3A mutations, indicated improved risk stratification 
(Renneville A et al., 2014; Shivarov V et al., 2013, Patel JP et al., 2012; Shen Y et al., 2011).  
 
1.3 De novo methyltransferase 3A: 
DNA methylation status as well as covalent histone modifications, chromatin remodelling 
functions and interfering RNA are epigenetic regulating mechanisms (Schoofs T & Mueller-
Tidow C, 2011) and have an important impact on carcinogenesis (Munoz P et al., 2012). In 
particular aberrant changes in DNA methylation patterns are a hallmark of cancer cells 
(Yamashita Y et al., 2010). Recently, it has also been reported that DNA methylation has 
crucial influence on key transcription factors, like WT1 and RUNX1, during the development 
of myeloid progenitor cells (Rönnerblad M et al., 2014; Qu Y et al., 2014). Three different 
types of DNA methyltransferase enzymes have been classified: DNA methyltransferases 
(DNMTs) 3A and B which both mediate de novo methylation while in contrast DNMT1 
mainly maintains methylation (Ribeiro AFT et al., 2012, Cagnetta A et al., 2014). DNMT3A 
has been shown to be repeatedly mutated in myeloid malignancies (Yan XJ et al., 2011; Ley 
TJ et al., 2010). This de novo methyltransferase 3A catalyses the addition of a methyl group 
donated from the cofactor S-Adenosyl methionine to the 5’-position of cytosine residues at 
CpG dinucleotide residues (known as CpG islands) in DNA (figure 2) which are located 
mainly in the promoter region of genes.  
 
Figure 2: Enzymatic function of DNMT3A (adapted from: Shih AH et al., 2012) 
However, increased methylation of CpG islands in the promoter region is somehow corre-
lated with reduced expression of the downstream gene and represents a regulatory mechanism 
of gene expression (Ley TJ, Ding L & Walter M, 2010; Munoz P et al., 2012). The affected 
genes involve tumour suppressor genes and their inactivation is considered to partially initiate 
leukaemogenesis (Agrawal S et al., 2007).  
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In contrast, the global methylation status of AML cells outside CGI islands is mostly 
hypomethylated which might lead to increased genomic instability and contribute to the 
malignant process (Eriksson A et al., 2015; The Cancer Genome Atlas Research Network, 
2013).  
 
1.4 DNMT3A mutations: 
Frequency and structure:  
DNMT3A mutations occur in approximately 22% of adult AML patients and are especially 
common in cases with intermediate risk normal cytogenetic AML (up to 36%) (Ley TJ et al., 
2010; Thiede C, 2012). The majority of the DNMT3A mutations (60-83%) affect codon R882 
which is allocated in exon 23 in the catalytic domain of the DNMT3A gene (Ley TJ et al., 
2010; Yamashita et al., 2011; Renneville A et al., 2012; Marcucci G et al., 2012; Ibrahem L 
et al., 2015). Figure 3 illustrates the structure of the DNMT3A gene: The elements of the 
regulatory region, namely the tetrapeptide PWWP domain and the polybromo homology 
(PHD) domain; and the methyltransferase (MTase) component which represents the catalytic 
region of the enzyme.  
 
Figure 3: Structure of the DNMT3A gene, PWWP = proline-tryptophan-tryptophan-proline 
domain, PHD = polybromo homology domain, MTase = methyltransferase domain (Adapted 
from: Yamashita Y et al, 2010) 
Characterisation of R882 mutations: 
The majority of mutations at the R882 hotspot (within the catalytic domain of the DNMT3A 
gene) are heterozygous and caused by different missense base sequences: Notably, the 
R882H mutation, a G-to-A transition producing histidine substitution instead of arginine; the 
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R882C mutation, a C-to-T transition leading to cysteine substitution and the R882S mutation, 
a C-to-T transversion resulting in serine substitution. They occur with different frequencies: 
62-65% R882H, 24-36% R882C and 2-3% R882S of all R882 mutations (Ley TJ et al., 2010; 
Brewin JN et al., 2012; Gaidzik et al., 2013).  
 
Effects of the mutation: 
Most of the somatic DNMT3A mutations prevent the formation of active homotetramers and 
heterotetramers between DNMT3A and DNMT3L which serves as a coactivator of the 
functionally active enzyme (Eriksson A et al., 2015; Shih A et al., 2012).  
The R882 mutation results in a decreased catalytic activity (50-80%) compared to wild type 
and a loss in DNA binding affinity (Yamashita Y et al., 2010; Russler-Germain DA et al., 
2014). 
Interestingly, the frequent R882H mutation does not appear to alter the methyltransferase 
activity when analysed as an in vitro mix of WT and R882H mutated enzyme. Yet, the 
coexpression of both proteins in mammalian cells results in loss of enzymatic function 
indicating that the R882H mutation causes haploinsufficiency in the sense of a dominant-
negative effect on the WT protein (Stewart H, et al., 2015; Genovese G et al., 2014; Russler-
Germain DA et al., 2014). 
These findings are deduced from in vitro experiments and have recently been further 
analysed in in vivo studies: Loss of DNMT3A function in murine haematopoietic stem cells 
(HSC) impairs their differentiation and interferes with normal haematopoiesis which leads to 
the development of several lymphoid and myeloid malignancies. Those DNMT3A-knock-out 
mice have an aberrant methylome pattern and underline the preleukaemic function of the 
mutation (Mayle A, et al., 2015). 
Furthermore, the methylation pattern in humans with CN-AML and DNMT3A mutations is 
different from those without the mutation: recent data reveals significant hypomethylation of 
the homeobox genes affecting embryogenesis as well as hematopoietic development and 
leukemogenesis (Qu Y et al., 2014). 
 
DNMT3A mutations in clonal evolution of AML: 
The impact of the DNMT3A mutation on the clonal evolution and pathogenesis of AML was 
examined by a comparison of the karyotypes of M3-AML with the fusion gene PML-RARA 
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as the known initiating event to M1-AML cases with normal cytogenetics and exomes of 
haematopoietic stem cells from healthy donors. Because of the pattern of DNMT3A mutations 
and co-occurring mutations like NPM1, IDH1, FLT3 and others DNMT3A mutations were 
thought to be initiating events in AML in cases with normal cytogenetics rather than random 
or background mutations in the hematopoietic stem cell and therefore contribute to AML 
pathogenesis as a “key initiating mutation” (Welch JS et al., 2012). 
Further research groups provide evidence that DNMT3A mutations contribute to clonal 
expansion of haematopoietic stem or progenitor cells as a result of impaired differentiation 
and represent an initiating event and respectively act as an oncogene during the development 
of AML (Genovese G et al., 2014; Roy DM et al., 2014).  
Moreover, DNMT3A mutations are considered as potential driver mutations because they 
seem to arise mutually exclusive to transcription-factor fusions that were previously 
acknowledged to advance leukaemia (Kihara R et al., 2014). The influence of the analysed 
mutation on clonal expansion is even more pronounced in relation to different age groups 
resulting in increasing percentages of leukaemia-associated genetic alterations in patients 
above 70 years of age (Xie M et al., 2014; Jaiswal S et al., 2014). 
Recent data confirms the role of DNMT3A as a driver mutation in the specific case of clonal 
haematopoiesis and development in AML in patients with aplastic anaemia (Yoshizato T et 
al., 2015).  
 
Clinical characterisation of patients with DNMT3A mutations:  
DNMT3A mutations are mostly seen in AML subtype M4 and M5 (after the French-American 
British morphological classification). Moreover, patients with DNMT3A mutations present 
with a higher peripheral white blood count at time of first diagnosis and also often harbour 
NPM1, IDH1/2, FLT3-ITD and TKD mutations but not CEBPA and NRAS mutations 
compared to patients with AML without DNMT3A mutations. The DNMT3A mutation is 
recurrently observed in patients older aged 50 and over rather than in younger patients 
(Kihara R et al., 2014). Importantly, DNMT3A mutations are associated with decreased 
overall and relapse free survival especially in patients of younger age (below 60 years) with 
cytogenetically normal AML (Thiede C, 2012; Ribeiro AFT et al., 2012; Renneville A et al., 
2012; Ibrahem L et al., 2015). Furthermore, the mutation presents as an independent adverse 
prognostic factor in high-risk genotypes as defined by criteria of the European Leukaemia 
Net (Shivarov V et al., 2013). 
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Treatment options:  
Aberrant DNA methylation is also the pharmacological target of inhibitors of DNA 
methyltransferases. The hypomethylating agent decitabine is already licensed as a first line 
therapy for the treatment of older AML patients who seem too frail to sustain standard 
induction chemotherapy (DiNardo CD et al., 2014; Ramos F et al., 2014). Elderly AML 
patients with a DNMT3A mutation have a significantly better response rate after treatment 
with decitabine than those without the mutation (Metzeler KH et al., 2012). However, there is 
also contradictory data showing the high-complexity between epigenetic mutations and 
hypomethylating drugs as well as the need for further studies (DiNardo CD et al., 2014).  
In terms of maintenance therapy a phase 1 b study demonstrated that lenalidomide which is 
beneficial in high-risk myelodysplastic syndrome in combination with azacitidine might 
control DNMT3A positive residual disease and therefore protect patients from clinical relapse 
(Wei A et al., 2015). 
Another approach for induction therapy of DNMT3A carriers is the comparison of the 
treatment with idarubicin versus daunorubicin. This study conducted by LaRochelle O et al. 
(2011) indicates that patients with DNMT3A exon 23 mutations have better median disease 
free and overall survival rates than those without the mutation when treated with idarubicin. 
Both patient groups have similar results when treated with daunorubicin (LaRochelle O et al., 
2011).  
Furthermore, patients with DNMT3A mutations seem to have a better response and improved 
overall survival after induction chemotherapy with high-dose daunorubicin (cytarabin plus 90 
mg daunorubicin/m
2
) in comparison to standard dose (cytarabin plus 45 mg daunorubicin/m
2
) 
than patients without the DNMT3A mutation (Patel JP et al., 2012).  
 
1.5 DNMT3A mutations as prognostic marker in AML: 
Patients with cytogenetically normal AML harbouring DNMT3A mutations have significantly 
shorter event-free (EFS) and overall survival (OS) with a 5 year EFS of 13% vs. 32% and an 
OS of 23% vs. 45% (accordingly a 2-year OS of 41% versus 68%) as compared to those 
without the DNMT3A mutation (Renneville A et. al, 2012; Renneville A et al., 2014). The 
EFS and OS were also significantly worse in the comparison of DNMT3A mutation versus 
DNMT3A wild type when all AML risk groups were taken into account; with a median OS of 
11.9 months when carrying the DNMT3A mutation against 24.0 months when the mutation 
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was absent. These findings were confirmed even when codon R882 in exon 23 alone was 
analysed as it contains most of the mutations within the DNMT3A gene (Ribeiro AFT et al., 
2012; Ostronoff F et al., 2013). 
In univariate and multivariate analyses DNMT3A mutation status was defined as an 
independent adverse prognostic factor for overall survival in the majority of patient 
subgroups above all in CN-AML patients (Renneville A et. al., 2014; Hou HA et al., 2013; 
Ribeiro AFT et al., 2012; Thol F et al., 2011). Kihara R et al. showed that the original 
European Leukemia Net risk stratification system for CN-AML could be improved by 
assigning patients with the DNMT3A mutation rather to the intermediate risk I group than to 
the favourable risk group (Kihara R et al., 2014; Dohner et al., 2010). In a recent meta-
analysis examining 6377 AML patients including 1161 DNMT3A mutation carriers the 
mutation appeared to predict an adverse OS for various patients risk groups as well as in the 
total non-classified population. Apart from the favourable risk subgroup and the non-R882-
DNMT3A mutant subgroup all other allocated patients were clearly stratified by DNMT3A 
prognostic status (Tie R et al., 2014). 
Several studies showed that patients with DNMT3A mutations have a significantly shorter 
overall and disease-free survival, this appeared not to be an effect of a decreased rate of 
complete remission (CR), but reflected an increase in disease recurrence as CR rates were 
shown to be similar between DNMT3A mutant and DNMT3A wild type patients (Thiede C, 
2012). In addition to that, AML patients with DNMT3A mutation suffered from higher 
relapse rates (Hou H et al., 2012). 
 
1.6 Minimal residual disease detection: 
Although 50-80 % of adult AML patients reach complete remission after treatment with 
chemotherapy, the great majority of these patients will finally sustain disease relapse 
resulting in long-term survival rates of 30-40% in younger patients and 20% in elderly 
patients (Buccisano F et al., 2012). The main cause of relapse is minimal residual disease 
(MRD). This term describes residual leukaemic cells that remain in patients' blood and bone 
marrow after chemotherapy or stem cell transplantation and cannot be detected by 
conventional morphological methods. Measurement of MRD provides crucial prognostic 
information as it allows further subdivision of the large intermediate risk AML group into 
MRD-positive and MRD-negative (above and below of a certain threshold as defined by the 
methodology applied) (Paietta E, 2012). This has important clinical implications for the 
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assessment of response after chemotherapy and possible postremission procedures to evaluate 
the patient's individual risk of relapse (Buccisano F et al., 2012). Moreover, MRD levels 
could also be used as a relative end point to compare treatment efficiencies at any point 
during AML treatment (Paietta E, 2012). One of the main limitations of MRD detection is the 
lack of consistency of gene mutations during disease progression.  
However, DNMT3A mutations appear to remain stable during AML disease evolution as 
several studies of sequential AML samples reveal. In these studies, AML patients with 
initially positive DNMT3A mutation status lacked the DNMT3A mutation at remission but 
regained the same mutation at disease relapse (Hou H-A et al., 2012; Pløn et al., 2014). 
Additionally, DNMT3A mutations seem to persist (or remain stable) from diagnosis to relapse 
and might induce other mutations, namely the FLT3-ITD mutation (Wakita S et al., 2012). In 
accordance with these observations, all patients in whom DNMT3A mutations were absent at 
initial diagnosis maintained this status at relapse or had mutations at low allele frequencies. 
These results indicate that the DNMT3A mutation could be applied as an effective biomarker 
for minimal residual disease (Hou H-A et al., 2012; Wakita S et al., 2012; Krönke et al., 2013; 
Pløn et al., 2014; Mancini M et al., 2015). 
 
1.7 Methods to detect DNMT3A: 
Up to now, the following techniques to detect DNMT3A mutations are available: direct 
Sanger sequencing of PCR amplified genomic or complementary DNA (Hou H-A et al., 
2012), denaturing high-performance liquid chromatography (dHPLC or WAVE
TM
 system) 
(Ribeiro AFT et al., 2012), high resolution melting curve (HRM) analysis (Singh RR et al., 
2012) and next-generation sequencing (Brewin et al., 2012; Shivarov V et al., 2014; Gorniak 
P et al., 2015). Although next-generation sequencing procedures have undergone many 
improvements they are still complicated and time consuming techniques that are neither 
available in average hospital laboratories nor suitable for large sample numbers and therefore 
do not represent an ideal method to test for DNMT3A mutations (Yamashita Y et al., 2010, 
Berenstein R et al., 2014). Direct Sanger sequencing was considered as “gold standard” for 
detection of somatic mutations yet it is certainly limited due to its relatively low sensitivity of 
10-20% mutant allele burden (Shivarov V et al., 2014; Gorniak P et al., 2015). 
High resolution melting curve analysis was reported to have a sensitivity of 6.7% for exon 23 
DNMT3A mutations (Singh RR et al., 2012) to about 2.5% (Hayette S et al., 2012) but has 
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limitations as the accuracy of the assay is highly dependent on the resolution of the machine 
used (Wittwer CT, 2009).  
Hitherto, although its high prognostic value, as has been demonstrated in 1.5, no simple 
screening test for detection of the DNMT3A mutation has been established yet. A fast 
determination of DNMT3A status could provide the attending physician with valuable 
information about potential treatment strategies and predict an individual outcome for the 
affected patient.  
Furthermore, the current DNMT3A MRD tests do not supply results that are accurate enough 
to monitor patients post treatment on residual leukaemic cells harbouring the DNMT3A 
mutation. 
 
1.8 Quantitative polymerase chain reaction: 
Quantitative polymerase chain reaction (qPCR) has been established as a reliable test for 
MRD detection for patients carrying genetic alterations with high sensitivities (depending on 
the target structure) (DiNardo CD & Luger SM, 2012).  
Quantitative PCR is based on the principle that detection of the PCR product is measured 
while the reaction still proceeds. It is therefore also called real-time PCR. qPCR has been 
developed from traditional PCR which can be divided up into 3 sections (figure 4): 
 
Figure 4: PCR phases 
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1.: Exponential: During the exponential phase the PCR product doubles every cycle if the 
reaction has 100% efficiency because the reagents are available in abundance and the 
reaction’s kinetics optimal for amplification. 
2.: Linear: The reaction slows down due to depletion of the reagents and the product is not 
duplicated at each cycle any more. 
3.: Plateau: The PCR reaction has finished, each experimental sample at its own plateau 
following the reaction’s kinetics. In traditional PCR the product is measured during this phase. 
While using qPCR the product is measured during the exponential phase because the 
amplification rate is stable enough to give precise results for quantification of a target 
structure. In order to detect the product a fluorescent probe that is complementary to one 
section of the amplicon is added to the reaction. This oligonucleotide probe (in the present 
sample similar the original trademark Taqman©) contains a fluorescent reporter at the 5’ end 
and a quencher at the 3’ end which suppresses the fluorescent group as long as the probe is 
intact. Due to its intrinsic exonuclease ability the DNA polymerase synthesizing the new 
fragment cleaves the quencher from the probe (Figure 5) allowing absorbance of the 
fluorescence by the qPCR machine. Therefore, the amount of fluorescence increases directly 
proportionally to the accumulation of new DNA strands (Dale J, 2012). 
 
Figure 5: Taqman© style qPCR detection (Reproduced from Wang SQ et al., 2010) 
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To enable quantification of a target structure, like in this case that of a specific mutation, the 
following terms are of great importance: The cycle threshold (Ct) which describes the PCR 
cycle number during which the fluorescence of the reporter dye reaches a level higher than 
the background called the threshold line. The threshold line is usually automatically allocated 
by the qPCR machine.  
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II. Aims 
On the basis of the reasons argued in the introduction, our aim was to establish two assays for 
detection of DNMT3A mutations: 
Firstly, we sought to develop a rapid screening test using differential restriction digestion of 
PCR amplified DNA products for reliably detecting the presence of an R882 mutation of the 
DNMT3A gene and determining the most common types of the R882 mutations within a few 
hours of bone marrow aspiration.  
Secondly, we aimed to establish a method for detecting and quantifying low copy numbers of 
DNMT3A R882 mutations for the purpose of monitoring minimal residual disease in AML 
patients.  
Both methods were designed to use the OCI/AML-3 cell line which harbours a heterozygous 
DNMT3A R882C mutation (Tiacci E et al.,2012; Brewin JN et al., 2012) as a positive control. 
Furthermore, after verification of results for the OCI/AML-3 DNA we intended to analyse 
AML patients’ samples. 
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III. Material and methods 
3.1 Material: 
3.1.1 Oligonucleotides: 
PCR: 
Forward Primer: 
5'-GTGATCTGAGTGCCGGGTTG-3'…………Sigma-Aldrich Company Ltd., Dorset, UK 
Reverse Primer: 
5'-TCTCTCCATCCTCATGTTCTTG-3'…………Sigma-Aldrich Company Ltd., Dorset, UK 
 
qPCR: 
Forward qPCR primer “DNMT3A green”: 5’-ACAGAAGATTCGGCAGAACTAAG-3’ 
Reverse qPCR primer “DNMT3A green”: 5’-CGGAGGACCAGCAGCCA-3’ 
Forward qPCR primer “DNMT3A yellow”: 5’-CCAGGGTATTTGGTTTCCCAGT-3’ 
Reverse qPCR primer “DNMT3A yellow”: 5’-ATGACTGGCACGCTCCATG-3’ 
Forward qPCR primer “DNMT3A blue”: 5’-CACCTCTTCGCTCCGCTG-3’ 
Reverse qPCR primer “DNMT3A blue”: 5’-TTTTTGTTTGTTTGTTTAACTTTGTGT-3’ 
All qPCR primer pairs were purchased from PrimerDesign Ltd., Southampton, UK. 
 
3.1.2 Enzymes: 
Ampli Taq Gold Polymerase……………………………..Life Technologies Ltd., Paisley, UK 
FastDigest AciI (SsiI)……………………………...Fisher Scientific Ltd., Loughborough, UK 
FastDigest AluI…………………………………….Fisher Scientific Ltd., Loughborough, UK 
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3.1.3 Cell lines: 
OCI/AML-3 cell line………………………Leibniz Institute DSMZ, Braunschweig, Germany 
KG-1 cell line………………………….American Tissue Culture Collection, Teddington, UK 
Cell line characteristics: Following information was taken out of the Guide to Leukemia-
Lymphoma Cell Lines (Drexler HG, 2010). 
 
	   OCI/AML-­‐3	   KG-­‐1	  
Age	  and	  sex	   57-­‐year-­‐old	  male	   59-­‐year-­‐old	  male	  
Sample	  type	   peripheral	  blood	   bone	  marrow	  
Doubling	  
time	  
35-­‐40	  hours	   40-­‐50	  hours	  
Immunology	  
CD3-­‐,	  CD4+,	  CD13+	  CD14-­‐,	  
CD15+,	  CD19-­‐,	  CD	  33-­‐,	  
CD34+,	  CD68+,	  HLA-­‐DR-­‐	  
CD3-­‐,	  CD4-­‐,	  CD13+,	  CD14-­‐,	  CD15+,	  CD19-­‐,	  
CD33+,	  CD34+,	  HLA-­‐DR+	  
Cytogenetics	  
hyperdiploid	  karyotype	  -­‐	  
48(45-­‐50)<2n>X/XY,	  +1,	  
+5,	  +8,	  
der(1)t(1;18)(p11;q11),	  
i(5p),	  del(13)(q13q21),	  
dup(17)(q21q25)	  -­‐	  
sideline	  with	  r(Y)x1-­‐2	  
hypodiploid	  with	  4.5%	  polyploidy;	  45(42-­‐
47)<2n>	  X/XY,	  -­‐4,	  +8,	  +8,	  -­‐12,	  -­‐17,	  -­‐20,	  
+2mar,	  der(5;17)(q10;q10)	  
del(5)(q?11q?13),	  dup(7)(q12q33),	  
del(7)(q22q35),	  i(8q)x2,	  
der(8)t(6;8)(p11;q22),	  
der(8)t(8;12)(p11;q13),	  
der(11)t(1;11)(q13-­‐21;p11-­‐
p13),der(16)t(?12;16)(?p13;q13/21)	  
Gene	  
alterations	  
NPM1	  mutation,	  
hemizygous	  for	  RB1,	  
DNMT3A	  R882C	  mutation	  
(Tiacci	  et	  al.,	  2012)	  
NRAS	  mutation,	  P15INK4B	  methylation,	  
P16INK4A	  methylation,	  P53	  mutation,	  RB1	  
rearrangement	  
 
Table 1: Characteristics of the Cell lines used as positive and negative controls 
 
 16 
3.1.4 Reagents and kits: 
10,000X Ethidiumbromide…………………………VWR International Ltd., Lutterworth, UK 
100 bp PCR DNA ladder…………………………..Fisher Scientific Ltd., Loughborough, UK 
10X Tris Acetate-EDTA buffer…………………...Sigma-Aldrich Company Ltd., Dorset, UK 
6X Gel Loading Dye…..Glycerol, EDTA, Bromophenol Blue, Xylene Cyanol, distilled water 
Ampli Taq Gold PCR Master Mix……………………….Life Technologies Ltd., Paisley, UK 
Custom designed real-time PCR assay…………………PrimerDesign Ltd., Southampton, UK 
DNeasy blood and tissue kit……………………………………………..Qiagen, Crawley, UK 
Foetal calf serum………………………………………………………..Biosera, Ringmer, UK 
Genetic Analysis Grade Agarose…………………..Fisher Scientific Ltd., Loughborough, UK 
Histopaque 1077…………………………………..Sigma-Aldrich Company Ltd., Dorset, UK 
L-glutamine (100mM)……………………………………Life Technologies Ltd., Paisley, UK 
Nuclease-free water………………………………..Fisher Scientific Ltd., Loughborough, UK 
Penicillin (100 IU/ml)……………………………………Life Technologies Ltd., Paisley, UK 
Phosphate buffered saline…………………………Sigma-Aldrich Company Ltd., Dorset, UK 
Precision 2X qPCR Mastermix………………………...PrimerDesign Ltd., Southampton, UK 
QIAquick PCR Purification Kit…………………………………………Qiagen, Crawley, UK 
QuantiTect Reverse Transcription Kit…………………………………...Qiagen, Crawley, UK 
RPMI 1640……………………………………………….Life Technologies Ltd., Paisley, UK 
Streptomycin (100mM)…………………………………..Life Technologies Ltd., Paisley, UK 
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3.1.5 Equipment: 
Gene Amp PCR System 9700……………………………Applied Biosystems, Carlsbad, USA 
Power Pack 200…………………………..Bio-Rad Laboratories Ltd., Hemel Hempstead, UK 
Nanodrop 1000 Spectrophotometer…………………...Thermo Scientific, Loughborough, UK 
Syngene Bio Imaging Gene Flash…………………………….Synoptics Ltd., Cambridge, UK 
Stratagene Mx 3005P qPCR System…………………….Agilent Technologies, Cheshire, UK 
3.1.6 Software: 
Stratagene Mx3005P Software version 4.10……………..Agilent Technologies, Cheshire, UK 
Nanodrop 1000 Software version 3.7.0……………….Thermo Scientific, Loughborough, UK 
Minitab Statistical Software version 16…………………………..Minitab Ltd., Coventry, UK 
 
3.1.7 Databases: 
Tissue bank of the Medical Research Building Brighton and Sussex Medical School, UK 
Database of the National Center for Biotechnology Information NCBI, Bethesda, USA 
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3.2 Methods: 
3.2.1 Cell culture: 
The leukaemic cell lines OCI/AML-3 and KG-1 were cultured in a medium containing RPMI 
1640 supplemented with 10% foetal calf serum, 100mM L-glutamine, penicillin (100 IU/ml) 
and streptomycin (100 µg/ml). The cells were maintained at 37° with 5% CO2 in a humidified 
incubator and passaged at the ratio of 1:3 every three days (Stewart HJ et al., 2011). 
 
3.2.2 Preparation of patients' samples: 
The bone marrow aspirate was diluted at the ratio 1:1 with PBS, then pipetted onto 
Histopaque 1077 and centrifuged for 20 minutes at 450 x g. Next, the white cell layer was 
removed and placed into a 15 ml tube and washed with 10 ml PBS. The sample was 
centrifuged for 15 minutes at 250 x g. After removing the supernatant, the cell pellet was 
resuspended in 1ml PBS. Unless the cells were used immediately after the preparation, they 
were diluted 1:1 with cell freezing medium containing 20%v/v DMSO, 40%v/v FCS in 
Iscove’s modified Dulbecco’s medium, frozen and stored in liquid nitrogen (Stewart et al., 
2011). All patients agreed by written informed consent to analysis of their bone marrow or 
peripheral blood samples and the Brighton East Research Ethics Commission gave 
permission to perform the research. 
 
3.2.3 DNA extraction: 
DNA extraction of OCI/AML-3 and KG-1 cells as well as patients' blood mononuclear cells 
was performed using the QIAGEN DNeasy Blood & Tissue kit (Qiagen, Crawley, UK) 
according to the manufacturer’s instructions.  
The concentration and purity of the extracted DNA was analysed by spectrophotometry using 
Nanodrop 1000. 
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3.2.4 Serial dilutions: 
The OCI/AML-3 DNA concentration and KG-1 DNA concentration were both adjusted to 84 
ng/µl. An initial dilution consisting of 100 µl OCI/AML-3 and 100 µl KG-1 DNA was set up. 
50 µl of this assay was taken out and mixed in a fresh Eppendorf tube with 50 µl of KG-1 
DNA. This step was repeated 8 times. Finally, 10 different dilutions were completed (Table 
2). 
 
Table 2: Serial dilutions of OCI/AML-3 in KG-1 DNA 
 
3.2.5 Polymerase chain reaction: 
Polymerase chain reaction was performed to amplify the relevant region of the DNMT3A 
gene including codon R882. A PCR assay of 50 µl in total contained the following elements: 
25 µl Ampli Taq Gold Master mix, 20 – 22 µl RNAse and DNAse free water, 1 – 3 µl (100 – 
200 ng) genomic DNA, 1 µl forward primer and 1 µl reverse primer. The reaction settings 
were as described: Denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, 
and elongation at 72°C for 30 seconds for 35 cycles (Brewin JN et al., 2013). 
 
Dilution No. 
Serial dilutions: % OCI/AML-3 and 
KG1 
Serial dilutions: % 
mutation strand 
1 100 % OCI 50 % 
2 50 % OCI + 50 % KG1 25 % 
3 25 % OCI + 75 % KG1 12.5 % 
4 12.5 % OCI + 87.5 % KG1 6.25 % 
5 6.25 % OCI +93.75 % KG1 3.125 % 
6 3.125 % OCI + 96.875 % KG1 1.5625 % 
7 1.5625 % OCI + 98.4375 % KG1 0.78125 % 
8 0.78125 % OCI + 99.21875 % KG1 0.390625 % 
9 0.390625 % OCI + 99.60938 % KG1 0.1953125 % 
10 0.1953125 % OCI + 99.80469 % KG1 0.0976562 % 
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3.2.6 PCR product purification: 
The PCR product was purified using the QIAquick® PCR Purification Kit according to the 
manufacturer’s instructions except for the last step which was elution of DNA in 50 µl 
nuclease-free water instead of buffer. 
3.2.7 Restriction enzyme digestion: 
The purified PCR product was digested by two different rapid-digestion restriction enzymes: 
AciI and AluI. AciI specifically recognises the 4 base-pair sequence 5'-CCGC-'3 (Polisson 
and Morgan, 1990), cleaving between the two cytosine residues on the forward strand and 
between the guanine and cytosine on the reverse strand (Figure 6). 
 
Figure 6: AciI restriction site 
AluI recognises the nucleotide sequence 5'-AGCT-3', respectively 3'-TCGA-5' and cuts 
between the guanine and cytosine residue resulting in blunt ends both sides of the digested 
fragment (Figure 7).  
 
Figure 7: AluI restriction site 
Both AciI and AluI were advanced restriction enzymes for rapid DNA digestion enabling to 
completely digest 1µg of lambda DNA within 5 minutes. According to the manufacturer, no 
degradation of 1µg of lambda DNA as a result of nuclease contamination or star activity 
(reduced enzyme specificity due to prolonged incubation) after prolonged incubation for 4 
hours was detected (Product Information, Thermo Scientific).  
Both enzyme assays were set up using to the following protocol: 
PCR product:  10µl 
RNAse free water:   7µl 
10X FastDigest buffer: 2µl 
FastDigest enzyme:   1µl 
Each sample was mixed thoroughly, spun down by centrifugation for 30 seconds in a bench 
top centrifuge and incubated at 37°C in a water bath for 60 minutes.  
 
 21 
3.2.8 Gel electrophoresis: 
After the restriction enzyme digestion the samples were run out on a 1.5% agarose gel and 
stained with 10mg/ml ethidium bromide to confirm complete digestion. The gel was then 
looked at under a UV transilluminator allowing the analysis of size and molecular weight of 
the digested DNA fragments. 
3.2.9 Quantitative polymerase chain reaction: 
The digested samples were diluted serially in nuclease-free water to a final concentration of 
1:1000. Quantitative PCR was performed with following primer pairs: 
TTCTGCTGGGTTGTGAAACTCTAGGCAGTGATGACCTTACTACCTTTAAGGTCACAGAAACC
AGCACAGTGCCTGGCACATGGTTGGTGATCTGAGTGCCGGGTTGTTTATAAAGGACAGAAGA
TTCGGCAGAACTAAGCAGGCGTCAGAGGAGTTGGTGGGTGTGAGTGCCCCTGTCCCTGCACT
TCGGGTGGCTGCTGGTCCTCCGGGTCCTGCTGTGTGGTTAGACGGCTTCCGGGCAGCCTGGT
CTGGCCAGCACTCACCCTGCCCTCTCTGCCTTTTCTCCCCCAGGGTATTTGGTTTCCCAGTC
CACTATACTGACGTCTCCAACATGAGCCGCTTGGCGAGGCAGAGACTGCTGGGCCGGTCATG
GAGCGTGCCAGTCATCCGCCACCTCTTCGCTCCGCTGAAGGAGTATTTTGCGTGTGTGTAAG
GGACATGGGGGCAAACTGAGGTAGCGACACAAAGTTAAACAAACAAACAAAAAACACAAAAC
ATAATAAAACACCAAGAACATGAGGATGGAGAGAAGTATCAGCACCCAGAAGAGAAAAAGGA
ATTTAAAACAAAAACCACAGAGGCGGAAATACCGGAGGGCTTTGCCTTGCGAAAAGGGTTGG
ACATCATCTC 
CCGC = AciI site (destroyed by both R882H and R882C mutations) 
CCGC = further AciI sites 
GTGATCTGAGTGCCGGGTTG = forward primer sequence 
TCTCTCCATCCTCATGTTCTT = reverse primer sequence 
CCAGGGTATTTGGTTTCCCAGT = forward qPCR primer “DNMT3A R882 
codon” 
CATGGAGCGTGCCAGTCAT = reverse qPCR primer “DNMT3A R882 codon” 
CACCTCTTCGCTCCGCTG = forward qPCR primer “DNMT3A digestion 
control” 
ACACAAAGTTAAACAAACAAACAAAAA =reverse qPCR primer “DNMT3A 
digestion control” 
ACAGAAGATTCGGCAGAACTAAG = forward qPCR primer “DNMT3A loading 
control” 
TGGCTGCTGGTCCTCCG = reverse qPCR primer “DNMT3A loading 
control” 
Figure 8: Real-time PCR primer pair sequence 
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Figure 8 shows the DNA sequence of the DNMT3A gene up- and downstream from codon 
R882 flanked by the outer standard PCR primer pair. Within this amplicon 3 qPCR primer 
pairs were placed to produce three different fragments with and without an AciI restriction 
site (a 4 base pair sequence CCGC as it occurred at the R882 hotspot). The first qPCR primer 
pair served as an internal DNA loading control because it amplified up a fragment without an 
AciI restriction site. The second primer pair amplified the region containing the AciI 
restriction site which matched the R882 hotspot. This restriction site was destroyed if a 
DNMT3A R882 mutation occurred. The third primer pair generated an amplicon containing a 
further AciI restriction site that was used as a relative digestion control. 
The thermal profile of each qPCR run was as follows: Enzyme activation for 10 minutes at 
95°C, than denaturation for 15 seconds at 95°C and data collection for 60 seconds at 60°C. 
The last two steps were repeated for 50 times. 
Additionally, every run included DNA from OCI/AML-3 cell line which harbours a 
heterozygous DNMT3A R882C mutation as a positive control and KG-1 as a negative control.  
3.2.10 Calculations: 
Based on this, the mutational proportion of a sample could be calculated: The loading control 
fragment which was not cut by AciI was used to assess the amount of DNA present in each 
sample. The relative abundance of the R882 codon-containing fragment was then used to 
quantify the amount of mutant present in each sample (equation 1). 
m
cyg
M
)( −
=
γ
  (1) 
M = proportion of mutants present in the sample 
γ = correction factor to adjust for differential primer binding after mock-digestion (see also 
4.2.4) 
g = abundance of loading control fragments 
y = abundance of mutant fragments 
m = gradient of the calibration curve 
c = y-intercept of the calibration curve 
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The correction factor γ was calculated from mock-digestion experiments (see also 4. 2. 3. 1) 
and represented what the amount of sample should be multiplied by to equal the amount of 
loading control for an AciI-digested sample as the primer binding efficiency was altered after 
digestion. g and y were calculated by equation number 2 and 3 accounting for the 
amplification efficiencies of each primer pair as measured in a separate experiment (4. 2. 2): 
g = 1.8533
Ct of loading control amplicon 
 (2) 
y = 1.8538
Ct of R882 containing amplicon
   (3) 
m and c in equation number 1 were given by the slope of the calibration curve given by the 
equation of a line (equation no. 4) (for further information on the calibration curve see 4. 2. 4):  
y = mx + c     (4) 
with m = 0.5596 and c = 0.0328. 
Furthermore, the cutting efficiency of the restriction enzyme AciI was calculated by relating 
the relative abundance of the loading control amplicon to the digestion control amplicon and 
carried out as an internal quality control for each sample tested (equation number 5).  
1.7897
1.8533
CtDC
CtLC
C =     (5) 
C = Relative Cutting Efficiency 
Ct DC = Ct of digestion control amplicon  
Ct LC = Ct of loading control amplicon 
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3.2.11 Sanger sequencing: 
To confirm the generated results externally all samples were sent to Eurofins MWG Operon, 
Ebersberg, Germany and sequenced using the company’s value read tube service. Therefore, 
15 µl of purified PCR product per sample was analysed by Sanger sequencing.  
When the results were available, the sequence was compared to human reference DNA by 
using the Basic Local Alignment Search Tool provided by NCBI 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
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IV. Results 
4.1 Differential restriction enzyme assay: 
4.1.1 Restriction enzyme digestion pattern: 
The DNMT3A wild type PCR product contained an AciI recognition site (CCGC) at codon 
R882 and two other sites further downstream as illustrated in Figure 9. Therefore, AciI 
digestion and subsequent agarose gel electrophoresis showed one major fragment of 252bp 
length and three smaller fragments measuring 125bp, 51bp and 16bp which served as a 
control for complete digestion.  
GCCTGGCACATGGTTGGTGATCTGAGTGCCGGGTTGTTTATAAAGGACAGAAGATTCGGCAG
AACTAAGCAGGCGTCAGAGGAGTTGGTGGGTGTGAGTGCCCCTGTCCCTGCACTTCGGGTGG
CTGCTGGTCCTCCGGGTCCTGCTGTGTGGTTAGACGGCTTCCGGGCAGCCTGGTCTGGCCAG
CACTCACCCTGCCCTCTCTGCCTTTTCTCCCCCAGGGTATTTGGTTTCCCAGTCCACTATAC
TGACGTCTCCAACATGAGCCGCTTGGCGAGGCAGAGACTGCTGGGCCGGTCATGGAGCGTGC
CAGTCATCCGCCACCTCTTCGCTCCGCTGAAGGAGTATTTTGCGTGTGTGTAAGGGACATGG
GGGCAAACTGAGGTAGCGACACAAAGTTAAACAAACAAACAAAAAACACAAAACATAATAAA
ACACCAAGAACATGAGGATGGAGAGAAGTATCAGCACCCAGAAGAGAAAAAGGAAT 
 
CCGC = AciI site/codon R882 
CCGC = AciI site/downstream cutting controls 
AGCT = AluI site 
GTGATCTGAGTGCCGGGTTG = forward primer sequence 
TCTCTCCATCCTCATGTTCTT = reverse primer sequence 
 
Figure 9: DNMT3A sequence flanking the R882 codon 
The DNMT3A R882H, R882C and R882S codon mutations altered the CCGC sequence at 
position R882, which subsequently couldn’t be cut by AciI anymore and therefore lead to an 
aberrant band pattern on the agarose gel: An additional band at 303 bp representing the 
mutated allele that lost the AciI recognition site was visible next to the band at 252 bp of the 
non-mutated allele. The band of the mutant allele was 51 bp longer because the fragment was 
amplified up to the AciI recognition site further downstream in the gene. If the DNMT3A 
mutation was homo- or hemizygous the bands of 252 and 51 bp wouldn't be present. 
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In the case of the R882C and R882S mutation an AluI site (AGCT) was generated resulting 
in bands of 250 bp and 253 bp lengths respectively. DNMT3A wild type PCR product was not 
cut by AluI and displayed a 444 bp band on the gel (table 3). 
 
Table 3 (adapted from Brewin JN et al., 2012) (All mutations were considered as 
heterozygous). 
 
4.1.2 Restriction enzyme sensitivity: 
To determine the sensitivity of the restriction enzyme AciI heterozygous mutant R882C DNA 
from the OCI/AML-3 cell line was serially diluted with wild type DNA from the KG-1 cell 
line in the following ratios: 50%, 25%, 12.5%, 5% and 0.5%. Following this, PCR 
amplification was performed as described in 3. 2. 4 using all dilutions and pure wild type 
DNA. In subsequent gel electrophoresis the presence of the additional 302 bp band in the 
samples 50%, 25%, 12.5% and 5% proved that AciI could detect the mutation at sensitivity of 
at least 5% mutant to wild type copy number (figure 10) (Brewin JN et al., 2012).  
 
 
 DNA sequence 
Amino acid 
sequence 
(position 
880-884) 
Fragments after 
AciI digest (in bp) 
Fragments after 
AluI digest (in bp) 
Wild type ATGAGCCGCTTGG M S R L A 
252 + 125 + 51 + 
16 
444 (not cut by 
AluI) 
R882H 
mutation 
ATGAGCCACTTGG M S H L A 
303 + 252 + 125 + 
51 + 16 
444 (not cut by 
AluI) 
R882C 
mutation 
ATGAGCTGGTTGG M S C L A 
303 + 252 + 125 + 
51 + 16 
444 + 250 + 194 
R882S 
mutation 
ATGAGCAGCTTGG M S S L A 444 (not cut by 
AciI) 
444 + 253 + 191 
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Figure 10: AciI sensitivity for DNMT3A R882C mutated DNA (Reproduced from Brewin JN 
et al., 2012) 
 
4.1.3 Cell lines OCI/AML-3 and KG-1: 
OCI/AML-3 R882C mutated PCR product and KG-1 wild type PCR product were used as a 
positive and negative control respectively and run aside the unknown samples in each 
experiment (figure 11).  
 
Figure 11: Band pattern of AciI and AluI digestion of OCI/AML-3 and KG-1 cell line DNA 
(Reproduced from Brewin JN et al., 2012). 
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4.1.4 Patients’ samples: 
42 AML patients’ samples were screened in total (table 6 in chapter 4.4.1.). 39 of those were 
found to be DNMT3A negative, 2 DNMT3A R882H positive and 1 R882C positive. Figure 12 
illustrates one exemplary negative sample (WT) and the R882H and R882C mutated samples 
out of the AML patients' samples pool. The AciI digest resulted in complete digestion of the 
wild type and displayed 252 bp and 125 bp, the bands of 125 bp and 51 bp are not visible on 
figure 12. Both the R882C and R882H mutation lead to incomplete digestion with an 
additional band at 303 bp (figure 12). AluI digestion allowed differentiation between the 
R882C and R882H mutation and confirmed the presence of the R882C mutation 
demonstrated by two bands at 250 bp and 194 bp. Furthermore, 6 samples from patients 
suffering from other haematological diseases (mostly myelodysplastic and myeloproliferative 
syndromes) were tested. The presence of the DNMT3A mutation was excluded in all those 6 
haematological non-AML samples. 
 
Figure 12: Differential restriction enzyme digestion of PCR product of DNMT3A wild type 
(WT), R882H and R882C DNMT3A mutated DNA (Reproduced from Brewin JN et al., 2012) 
 
4.2 Quantification of the mutation: 
4.2.1 Principle of relative quantification: 
Quantity of the DNMT3A R882 mutation was measured relative to a calibrator which was a 
sample of known mutational proportion; in this case the heterozygous OCI/AML-3 PCR 
product. After verification of effective primer binding and amplification efficiencies a 
dilution series of the calibrator was performed to produce a calibration curve with the purpose 
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of evaluating the detection threshold for the R882 mutation. The patients’ samples to be 
analysed were then calculated by correlating the abundances of three independent amplicons 
flanking the R882 codon with the slope of the calibration curve (3. 2. 10).  
4.2.2 Amplification efficiencies of qPCR primer pairs: 
To test the amplification efficiency of each double dye (Taqman© style) qPCR primer pair a 
6-log serial dilution of OCI/AML-3 PCR product in nuclease-free water was made at the 
ratios of 10
-1
, 10
-2
, 10
-3
, 10
-4
, 10
-5
 and 10
-6
 and amplified using all three primer pairs.  
Based on this, Ct  values of the dilutions 10
-1 
- 10
-6
 were used for measurement of the primer 
amplification efficiency using the Ct slope method (Schmittgen & Livak, 2008). Therefore, 
the obtained Ct values were plotted against the logarithm of the corresponding PCR product 
dilution (figure 13). Amplification efficiencies were then calculated from the slope of these 
graphs according to the following equation (with Ex representing the efficiency): 
Ex = 10
(-1/slope) 
– 1  (6) 
For the loading control primer pair the slope of the line was – 3.7321 which lead to following 
calculations: 
Ex = 10
(-1/-3.7321)
 – 1  (7) 
    = 0.8533 or 85.33% 
This was equally done for the primer pair containing the R882 codon resulting in an 
efficiency of 85.38% and for the digestion control primer pair concluding in 78.97% 
efficiency. As the correlation coefficient (R²) of each graph was above 0.99, Ct values were 
precisely predicting the logarithmic concentration of PCR product. Due to experimental error 
one outlier was ignored in the digestion control primer graph so that data points of only 5 log 
dilutions are demonstrated.  
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Figure 13: qPCR primer pair amplification efficiencies 
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4.2.3.1 Primer binding efficiencies of digested PCR product: 
The primer binding qualities and effects on Ct values after AciI digestion of the PCR product 
were tested. Therefore, KG-1 wild type PCR product was digested according to the protocol 
(3. 2. 7.) and in a second assay mock-digested (all enzyme buffers added, only difference: no 
enzyme added). These two assays were then amplified by qPCR as described in 3. 2. 10 and 
following Ct values were measured: 
KG-1, Mock-
Digestion 
Loading 
control 
R882 codon 
amplicon 
Digestion 
control 
% Mutation 
% Relative 
Cutting 
Ct Replicate 1 17.01 16.95 17.99 - - 
Ct Replicate 2 16.76 16.93 17.75 - - 
Ct Replicate 3 17 17 17.89 - - 
Ct Replicate 4 16.81 16.94 17.77 - - 
Ct Replicate 5 16.48 16.94 17.68 - - 
Mean 16.81 16.95 17.82 - - 
KG-1, AciI-
Digestion 
Loading 
control 
R882 
amplicon 
Digestion 
control 
% Mutation 
% Relative 
Cutting 
Ct Replicate 1 18.15 23.63 22.46 0.11 95.11 
Ct Replicate 2 17.82 23.62 22.57 -0.60 97.93 
Ct Replicate 3 17.67 23.56 22.53 -0.77 98.51 
Ct Replicate 4 17.55 23.44 22.57 -0.77 99.28 
Ct Replicate 5 17.66 23.41 22.62 -0.50 99.00 
Mean 17.77 23.53 22.55 -0.51 97.96 
Standard 
deviation of 
the mean 
   0.16 0.75 
 
Table 4: Ct values of qPCR primer binding efficiency experiments 
For the mock-digested samples the Ct values of the loading control and the R882-containing 
amplicon were very similar with a difference of only 0.14 of a Ct value. The digestion 
control’s Ct value was higher which was probably due to the slightly lower amplification 
efficiency of that primer pair. For the AciI digested KG-1 PCR product the values for the 
loading control amplicon, the R882 amplicon and the digestion control amplicon were 
expected to be the same because KG-1 does not contain a DNMT3A mutation and therefore 
should be completely cut by the restriction enzyme. The fact that the loading control 
amplicon and the latter ones had different Ct values was incorporated into the mutation 
calculations as correction factor γ (3.2.10). 
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4.2.3.2 Measuring the relative cutting efficiency:  
The relative digestion efficiency was measured by comparing the Ct of the digestion control 
amplicon of AciI-digested DNMT3A KG-1 against the Ct of the digestion control amplicon of 
the mock-digested KG-1 sample (table 4). As the patient samples were very limited it was not 
possible to run a mock-digestion control for each sample. However, the mean of the Ct values 
for the mock-digested digestion control and the mean of the Ct values for AciI-digested 
loading control on KG-1 PCR product (table 4) were very much alike (difference of 0.05 Ct 
values), therefore it was considered as valid to estimate the cutting efficiency on the 
difference in Cts of the digestion control and the loading control for each AciI digested 
patient sample.  
4.2.4 Calibration curve: 
The calibration curve was based on a qPCR experiment generating multiple amplicons of a 
serial dilution series of OCI/AML-3 DNA in wild type/KG-1 DNA at the following ratios: 
Dilution 
No. 
Serial dilutions % OCI/AML-3 
Serial dilutions % 
mutation strand 
1 100 % OCI 50 % 
2 50 % OCI + 50 % KG-1 25 % 
3 25 % OCI + 75 % KG-1 12.5 % 
4 12.5 % OCI + 87.5 % KG-1 6.25 % 
5 6.25 % OCI +93.75 % KG-1 3.125 % 
6 3.125 % OCI + 96.875 % KG-1 1.5625 % 
7 1.5625 % OCI + 98.4375 % KG-1 0.78125 % 
8 0.78125 % OCI + 99.21875 % KG-1 0.390625 % 
9 0% OCI + 100 % KG-1 0 % 
 
Table 5: Dilution series of OCI/AML-3 in KG-1 DNA  
Dilutions No. 1-9 using the OCI/AML-3 cell line were shown to have the mutational load 
detailed above. Due to its heterozygosity the percentage of the DNA strand containing the 
mutation is half of the amount of OCI/AML-3 DNA in each dilution. Figure 14 demonstrates 
how the mathematical quantification of DNMT3A R882 mutation based on experimental Ct 
values was consistent with the actual percentage of the mutation created by the dilution series. 
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The y axis represents the experimentally detected/calculated proportion of mutants whereas 
the x axis symbolises the proportion of mutant cells in the dilution samples. In other words, 
the graph depicts the relationship of the detected proportion and the actual proportion of 
mutant percentage in the samples and contains errors bars of 2% which equalises to 1% 
mutant DNA.  
 
Figure 14: Calibration curve (Reproduced from Bisling KE et al., 2013) 
 
4.2.5 Sensitivity of the MRD detection assay: 
The sensitivity of the MRD detection assay was determined by the calibration curve using the 
OCI/AML-3 dilutions as mentioned above. The lowest concentration of mutant in wild type 
DNA that could still be amplified and detected was 0.78% of OCI/AML-3 R882C mutant 
DNA in KG-1 wild type DNA. Further dilutions containing 0.39% and 0.19% of OCI/AML-3 
DNA could not be reliably amplified and detected. 
Therefore, the sensitivity of the assay was declared as less than 1% of total cells respectively 
0.5% of allele frequency (assuming heterozygosity among the samples carrying the mutation).  
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4.2.6 Precision of qPCR replicates: 
A minimum of two technical qPCR replicates was performed for each AML sample. To test 
the precision of these replicates mean Ct values were calculated and plotted against the 
minimal and maximal replicates (Figure 15). In guidelines on MRD analysis Van der Velden 
and colleagues (2003) suggest that the variation in Ct values with a mean of below 36 should 
not vary more than 1.5. In this project most of the qPCR replicates are within the appropriate 
range as demonstrated in figure 15.  
 
Figure 15: Experimental variation range of the qPCR replicates 
 
4.2.7 Reproducibility: 
All AML samples were repeated once in a separate qPCR. The results of the mutation 
calculation based on the first qPCR and second qPCR values were analysed by paired 
Wilcoxon test. No statistically significant difference was found between both measurements 
(p=0.186, n=22). This was confirmed by using paired t-test on the same data set to test 
whether there was a significant difference between both observations (95% CI -2.94, 1.006; 
p=0.388). However, the analysis by paired t-test confirmed that the results were reliably 
reproducible.  
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4.2.8 Patients’ samples: 
19 patients who had been previously screened by the rapid digestion assay were additionally 
analysed by the quantification method/MRD assay. 3 patients out of this pool relapsed and 
were retested so that in total 22 AML samples were tested. 2 patients harboured the DNMT3A 
R882H mutation and were quantified as 97.6 ± 1.9% and 71.1 ± 3.3% of total cells (or 48.8 ± 
0.95% and 35.55 ± 1.65% mutant allele frequency respectively). These amounts represent the 
mean of separate calculations (listed in 3. 2. 10) based on precise Ct values as detected by the 
qPCR machine of each technical replicate and the corresponding standard deviation. The 
remaining 20 samples were negative for the DNMT3A R882 mutation. OCI/AML-3 and KG-
1 PCR product were used as positive and negative controls in each experimental run to 
standardise the reaction and following calculations. The following scheme (figure 16) 
demonstrates the qPCR graphs of the loading control amplicon (labelled as LC), the R882 
codon containing amplicon (labelled as R882) and the digestion control amplicon (labelled as 
DC) for a typical negative patient sample, the R882H positive patient sample and OCI/AML-
3 as positive and KG-1 negative control for one experimental run. The x axis represents the 
qPCR cycle number and the y axis shows the level of fluorescence detected.  
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Figure 16: qPCR curves for three primers pairs for the mutated OCI/AML-3 and control KG-
1 cell line (top) and for patients’ samples (below) (Reproduced from Bisling KE et al., 2013) 
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4.3 Sequencing: 
The mutational status of all analysed patients was confirmed by Sanger sequencing. The 
detected mutations (two R882H mutations, one R882C mutation) were consistent with the 
sequencing results. Furthermore, all negative samples were confirmed to lack the DNMT3A 
R882 mutation.  
 
Figure 17: Sequencing results (Reproduced from Bisling KE et al., 2013) 
Figure 17 displays the base and amino acid sequence of a typical wild type patient sample, 
one of the two patient samples harbouring the R882H mutation and the patient sample 
carrying the R882C mutation. The R882H mutation was caused by a G-to-A transition 
leading to a histidine substitution at codon position 882 in exon 23 which caused loss of an 
AciI restriction site. The R882C mutation was generated by a C-to-T transition causing 
cysteine substitution which resulted in loss of the AciI site but generation of an AluI 
restriction site (Brewin JN et al., 2013).  
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4.4 Clinical characteristics of the patients: 
4.4.1 Clinical details of all patients’ samples: 
42 AML and 6 MPN/MDS samples were screened using the rapid screening test. 19 AML 
samples were further analysed with the MRD detection assay. Table 6 and 7 summarise the 
clinical characteristics including age, sex, percentage of bone marrow blasts, the sample’s 
origin, type of AML, karyotype and the allocated risk status of the AML and MPN/MDS 
samples.  
 
Table 6: Clinical characteristics of the 42 AML samples. N/A means information not 
available, ± values are means plus/minus standard deviation of the mean; BM = Bone marrow, 
PB = Peripheral blood, risk status was stratified according to the Cancer and Leukemia Group 
B (CALGB 8461) (Byrd JC et al., 2002) 
 
 
 
Variable AML samples (N=42) 
Age at time of bone marrow biopsy – yrs. 64.2 ± 11.2, 1 N/A 
Male sex – no. (%) 21 (53%), 2 N/A 
Bone marrow blasts– (%) 41.8 ± 30.6, 12 N/A 
Origin of sample – BM/PB 35: BM, 6: PB, 1 N/A 
Type of AML – no. (%): 1 N/A 
- De Novo AML 27 (64%) 
- Secondary AML 10 (24%) 
- Relapsed AML 4 (10%) 
Normal karyotype – no. (%) 23 (55%) 
Risk status – no. (%):  
- Favourable 1 (2.4%) 
- Intermediate 27 (64.3%) 
- Adverse 4 (9.5%) 
- Indeterminate 10 (23.8%) 
 39 
Other malignant diseases: 
The following non-AML bone marrow samples were screened because the DNMT3A 
mutation was not only identified in patients with DNMT3A but also in cases with 
myelodysplastic syndromes and myeloproliferative neoplasms (Stegelmann F et al., 2011; 
Walter MJ et al., 2011). 
 
 
Age 
(years) 
Sex Disease 
Further 
details 
BSMS 14 47 N/A Polycythaemia JAK 2 pos. 
BSMS 28 63 M 
Monoclonal gammopathy of undetermined 
significance 
 
BSMS 53 73 F Chronic myeloid leukaemia BCR-ABL 
BSMS 66 64 F Refractory anaemia with excess blasts type 2 Blasts: 12% 
BSMS 88 68 M 
Refractory cytopenia with multilineage 
dysplasia 
JAK 2 pos. 
BSMS 90 76 M Refractory anaemia with excess blasts Blasts: 22% 
 
Table 7: Diagnostic and cytogenetic details of the 6 haematologic non-AML samples that 
were tested for the DNMT3A mutation 
 
Furthermore, all AML patient samples were analysed regarding any clinical differences 
between the ones harbouring the DNTM3A R882 mutation and those classified as wild type 
for DNMT3A (table 8).  
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Comparison of DNMT3A R882 mutation versus DNMT3A R882 wild type: 
Variable 
DNMT3A R882 
Wild type (N=39) 
DNMT3A R882 
Mutation (N=3) 
p Value 
Median age – in yrs. (range) 66.00 (23-82) 78.00 (76-80) [1] 0.0736٭ 
Male sex – no. (%) 19 (50) [1] 2 (100) [1] 0.4885† 
Median bone marrow blast count – 
in % (range) 
30.8 (1-98) [11] 58.0 (17-99) [1] 0.3827٭ 
Type of AML – no. (%): [3]   
- De Novo AML 
26 (66.67)  2 (66.67) 1† 
- Secondary AML 
6 (15.38) 1 (33.33) 0.43† 
- Relapsed AML 
4 (10.26) 0 1† 
Normal karyotype – no. (%) 21 (53.85) 2 (66.67)  
Risk status – no. (%):    
- Favourable 
1 (2.6) 0 1† 
- Intermediate 
24 (61.5) 3 (100) 0.5414† 
- Adverse 
4 (10.3) 0 1† 
- Indeterminate 
10 (25.6) 0 1† 
 
Table 8: Numbers in [] brackets indicate how many patients didn't have appropriate values 
available and were omitted from statistical analysis.٭ p values were calculated with Mann 
Whitney U test for the comparison of DNMT3A wild type with DNMT3A R882 mutation. † p 
values were calculated using the Fisher exact test for the comparison between DNMT3A 
R882 wild type and DNMT3A R882 mutation. 
No statistically significant differences were observed between the AML patients carrying the 
DNMT3A mutation and those with wild type DNMT3A. However, there was a slight tendency 
towards higher age at disease presentation, the percentage of male sex, the occurrence of a 
higher blast count and the probability of the intermediate risk group status of patients 
carrying the DNMT3A R882 mutation than those without the mutation. 
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4.4.2 Clinical outcome of the patients with DNMT3A R882 mutation: 
The two patients harbouring the DNMT3A R882H mutation are referred to as BSMS 33 and 
BSMS 85: BSMS 33 was a 76-year-old male patient harbouring a deletion of the long arm of 
chromosome 5 (del(5)(q13q33)) which was identified at the time of initial diagnosis. Deletion 
of the long arm of chromosome 5 is a common monosomal karyotype in acute myeloid 
leukaemia and myeloprofilerative disease and is associated with an extremely unfavourable 
prognosis in AML patients (Breems DA, Van Putten WLJ, & Löwenberg B, 2013). He had a 
blast count of 99% at initial diagnosis and was positive for the FLT3-ITD mutation. The co-
occurrence of the NPM mutation as well as the CBFB or MLL gene rearrangement was 
excluded. In this project, the DNMT3A R882H mutation within his genome was quantified as 
71.1 ± 3.3% of total cells (or 35.55 ± 1.65% mutant allele frequency).  
BSMS 85 was also a male patient, aged 80 years, suffering from secondary AML as a 
progression of MDS with normal cytogenetics. He was allocated to the intermediate risk 
group (risk group allocation following indications of the Cancer and Leukemia Group B 
(CALGB 8461), Byrd JC et al., 2002) and he did not have a FLT3-ITD or NPM mutation.  
They both received 2 cycles of intensive chemotherapy consisting of Cytarabine as a 
continuous infusion for seven days plus Daunorubicin on days one until three. Both patients 
received morphological response to chemotherapy but an incomplete blast recovery and 
relapsed quickly post treatment. BSMS 33 survived for 7 months, BSMS 85 for 8 months 
after initial diagnosis. 
Unfortunately, there is only very limited clinical information on the patient with the 
DNMT3A R882C mutation: He was a male patient with primary AML and normal 
cytogenetics who died quickly after diagnosis. 
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V. Discussion 
5.1. Synopsis of principal findings: 
In this chapter the methodology and principal findings of both DNMT3A mutation detection 
assays will be argued and compared to other techniques. Briefly, genomic DNA was 
extracted from AML samples, PCR amplified and analysed by a rapid differential restriction 
enzyme digestion assay. By differentiating between two specific digestion enzyme patterns 
and confirmation through comparison with control cell line OCI/AML-3, three cases of 
DNMT3A R882 mutations could be identified. Two R882H and one R882C mutation were 
detected within the pool of 42 AML samples. In order to detect minimal residual disease with 
low copy numbers of DNMT3A mutations, the test was further expanded through quantitative 
PCR allowing quantification of the mutational proportion. A subset of 22 samples were 
further analysed using this highly sensitive test. The two R882H mutations could be 
confirmed and were calculated as 97.6% and 71.1% of total cells. However, DNMT3A R882 
mutations were not present in any of the other 20 samples. The clinical details of the patients 
harbouring the DNMT3A mutation were examined and compared to the patients that didn’t 
show the mutation but no statistically significant differences between both groups were 
recognised.  
 
5.2. Evaluation of the strengths and limitations of the DNMT3A detection assays: 
5.2.1 Differential restriction enzyme assay: 
The following paragraph will highlight the strengths and weaknesses of the differential 
AciI/AluI restriction enzyme assay: The biggest advantage of this method is the rapid 
determination of presence or absence of the most frequent mutations, namely the R882H and 
R882C mutations at the R882 locus within the DNMT3A gene. Only two to three hours in 
total is enough time to process an AML bone marrow sample. Another major strength is that 
the sensitivity of the test is 5% of mutant to wild type copy number. In addition, the test uses 
basic techniques such as DNA purification, PCR, restriction enzyme digest and therefore 
equipment that is broadly available in most diagnostic laboratories. Furthermore, it is a cost 
effective test as it requires mostly mass-produced, relatively inexpensive standard kits, e.g. 
PCR Mastermix (Brewin JN et al., 2013).  
 43 
On the other hand, a great disadvantage is the risk of potential incomplete digestion, hence 
the danger of falsely predicting the absence of the mutation. Normally, complete digestion 
should be confirmed by the two smaller fragments (16 bp and 51 bp) but it can be difficult to 
visualise smaller bands on agarose gels.  
A further limitation is that the test doesn't allow a differentiation between R882C and R882S 
mutations as it is not possible to distinguish a band with a 3 bp difference on a standard 
agarose gel. However, as the subtypes of the DNMT3A R882 mutation are rather of academic 
interest than of clinical relevance, this disadvantage is acceptable. 
Moreover, although each step of the method is fast and simple post PCR processing can make 
it fairly laborious.  
Another disadvantage is that the AciI enzyme digests the DNA leaving cohesive ends which 
could re-ligate if over digestion occurs. 
 
5.2.2 Choice of qPCR chemistry: 
Several different types of qPCR detection are available: The most common qPCR chemistry 
methods are Taqman©, SYBR Green, Molecular Beacons and MGB (3′-Minor groove 
binder-DNA) probes (Forlenza M et al., 2012). We chose Taqman© style double-dye probes 
because they provide precise results while being very cost effective. The only qPCR probe 
that is lower in costs is SYBR green but this probe has the disadvantage of non-specific 
primer binding and false-positive signals as SYBR Green does attach to any type of double 
stranded DNA. 
 
5.2.3 Relative quantification using internal amplicons: 
In this project, relative quantification of the DNMT3A mutation in comparison to absolute 
quantification (measuring the absolute copy number of a specific pathogen) was considered 
as sufficiently precise because the knowledge of the exact number of gene copies was not 
deemed necessary for the clinical application of this potential MRD assay. Rather, the 
project’s aim was to identify a certain percentage of cells in relation to a known reference. 
This reference is often a reference gene that is as similar to the target gene as possible. For 
this project an internal control instead of a separate reference gene was chosen because the 
mutational quantification was based on the difference in the amount of restriction enzyme 
digested amplicons. Therefore, these amplicons should be digested in exactly the same way 
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to prevent technical influence on quantification. The use of an internal control had also the 
practical advantage that only one sample (the DNMT3A sequence containing all three 
amplicons) was digested so that laboratorial work was shortened and the amount of 
restriction enzyme reduced. 
5.2.4 Calculations: 
5.2.4.1 Mutational proportion: 
The calculation of the mutation was based on a mathematical model for relative 
quantification in real-time PCR reactions by Pfaffl MW (2001) which estimates the relative 
expression ratio of a target gene in relation to a reference gene transcript by taking into 
account the PCR amplification efficiencies. For this project, this model was further refined by 
expressing the level of mutation in relation to a calibration curve, as usually done for absolute 
quantification, with the aim to obtain measurements as precise as possible. The benefit of this 
refined calculation method is that the results are corrected for differences in PCR efficiencies 
between target and control sample and that the threshold detection is defined very precisely 
through a calibration curve. An inconvenience of the refined efficiency correction method is 
the need for dilution series experiments of the target to create the standard curve. If several 
reference genes or internal controls are used this has a great impact on the laboratory time 
and effort. However, in the present case this disadvantage has less importance as only one 
internal control is used. Another option to estimate quantification is the comparative Ct 
method (2
-
ΔΔ
Ct
 method) which postulates several assumptions (Schmittgen TD & Livak KJ, 
2008). One of them is that the PCR efficiency is 100% which is why this method wasn’t 
appropriate for the present data setting.  
 
5.2.4.2 Relative cutting control: 
To confirm complete restriction enzyme digestion without having the facility to run a 
separate mock-digestion assay in each experiment, the relative cutting control was examined 
by comparing Ct values of the loading control and the digestion control amplicon of each 
AML bone marrow sample. The digestion experiments on KG-1 PCR product as described in 
4.2.3.2 resulted in very similar Ct values for the digestion control amplicon of the mock-
digested KG-1 PCR product and the loading control amplicon of the AciI digested KG-1 PCR 
product. This lead to the conclusion that the mock-digested digestion control could be 
replaced by the loading control amplicon of the AciI digested sample which was generally 
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applied in all subsequent experiments. However, this observation needs to be further 
validated by testing the stability of this phenomenon across different cell lines as well as bone 
marrow samples. This disadvantage of the MRD detection assay which could easily be 
improved in future experiments by adding a mock-digestion sample of each AML sample or 
by further analysing the consistency of the above mentioned Ct values.  
5.2.5 qPCR primer binding and amplification efficiencies: 
As literature on relative quantification of gene expression levels based on qPCR (Schmittgen 
TD & Livak KJ, 2008) suggested that primer amplification efficiencies of the target and 
control gene should be within 10% of each other, the primer efficiencies of the method 
established in this project were considered valid to estimate the proportion of the mutation, 
especially as the calculations were corrected for each primer amplification efficiency. 
However, the digestion control primer had a slightly lower efficiency of 79% which is 
downgrading the predictive value of the digestion control calculations. According to 
Schmittgen and Livak’s protocol primer amplification efficiencies should be at least 80%, 
therefore an adjustment of that primer might have been useful to improve the precision of the 
estimation of the digestion control. As mock-digestion experiments showed, there were small 
differences in Ct values due to potential qPCR inhibition by restriction enzyme buffers. These 
were corrected by a further correction factor obtained through comparisons of mock and 
enzyme digested PCR product, so that the calculations were as accurate as possible. In this 
model we assume that the altered primer binding qualities are similar when digested KG-1 
PCR product is amplified as well as patients’ samples or other cell lines. To prove this 
assumption further experiments are needed to confirm that the primer binding qualities are 
consistent across different cell lines and patients samples. 
 
5.2.6 Calibration curve: 
The use of a calibration curve offers great precision when measuring expression fold ratios or 
quantifying leukaemic cells (Forlenza M et al., 2012). In this project, the calibration curve 
was based on a dilution series with 9 different dilutions allowing the determination of the 
lowest possible detection threshold with great accuracy because the amount of mutant DNA 
was gradually decreased. On the other hand, the establishment of a calibration curve is 
laborious and requires very clear technical working as methodology is based on this curve. 
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5.2.7 Sensitivity and reproducibility: 
The limit of detection of the minimal residual disease assay was between 10
-3
 and 10
-4
 as the 
DNMT3A mutation was still reliably detected in less than 1% of leukaemic cells or 0.5% 
allele frequency respectively. This level complies with the requirements stated by VJH Van 
der Velden et al. (2003) and E Paietta et al. (2012) for detection of recurrent gene mutations 
in acute myeloid leukaemia. One restraint is that the sensitivity was measured based on 
dilution experiments of the DNMT3A R882C mutation so that the level of minimal detection 
is formally only confirmed for the R882C type of the mutations at the R882 hotspot. 
However, as the R882H mutation is based on the same mechanism, there should be no 
objections against transferring this level of detection to the R882H type of mutation. 
The reproducibility was tested by repeating the qPCR and subsequent mutation calculations 
leading to similar results based on statistical analysis by Wilcoxon test and paired t- test. A 
repetition of the experiments from the beginning including the initial PCR and especially the 
restriction enzyme digestion would have been more precise and would allow more realistic 
conclusions about the reproducibility of the assay. This should be taken into consideration in 
future experiments. 
 
5.2.8 DNMT3A mutation status and clinical characteristics of the AML samples: 
In this report, out of the AML sample pool containing 42 samples in total, two DNMT3A 
R882H mutations were detected and quantified as 97.7% and 71.1% respectively and one 
R882C mutation was detected but not further analysed due to depletion of the sample. 
Moreover, 20 other AML samples were screened using the quantification method and the 
absence of the DNMT3A R882 mutation was confirmed. 
The prevalence of the DNMT3A mutation usually has a range from 15 to 25% (Thiede C, 
2012). In this project, the prevalence of the DNMT3A R882 mutation was much lower, 
namely at the 7% level which is unusual and could be due to several different reasons, e.g. 
the small sample size, by chance or patient selection. As DNMT3A mutations most frequently 
arise in cytogenetically normal AML (CN-AML) with prevalence rates from 27.2% (Thol F 
et al., 2011) to 34.2 % (Marcucci G et al., 2012) we sought to analyse the mutational 
recurrence in patients with CN-AML in our sample pool. In this project, out of 23 patients 
suffering from AML with normal cytogenetics three were DNMT3A R882 mutant leading to a 
ratio of 13.04% in CN-AML. Potential explanations for this difference are mentioned above.  
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In most studies from Europe and the United States patients with AML harbouring the 
DNMT3A mutation were about 10 years older, of male sex, had a high blast count and 
typically presented with cytogenetically normal AML compared to those without the 
mutation (Tie R et al., 2014; Renneville A et al., 2014; Gaidzik VI et al., 2103; Thiede C, 
2012). There are tendencies towards these characteristics in the present patient cohort as well: 
Both were male, of older age, had a considerably elevated blast count and one of them had 
cytogenetically normal AML. The other patient differed in the genetic profile as he had a 
deletion of the long arm of chromosome 5. Furthermore, one of the two was positive for the 
FLT3-ITD mutation which has been observed as a frequent co-occurrence of DNMT3A 
mutations (Abdel-Wahab O & Levine RL, 2013). However, no statistically significant 
differences were observed between patients with the DNMT3A mutation compared to those 
without the DNMT3A mutation. One possible reason for this is that only a small number of 
patients was analysed as only a limited number of patients were diagnosed with acute 
myeloid leukaemia during the study period in East Sussex. Another reason could be the fact 
that patients with AML were analysed at all points during their treatment, not only ones with 
primary AML but also those with relapsed disease (see table 8, 4.4.1.) which could 
potentially reduce the number of patients with DNMT3A mutations and mask their typical 
presentation. 
An advantage of this patient cohort was that 3 patients had samples available at initial 
diagnosis and also at relapse. Analysis showed that these patients were DNMT3A mutation 
negative at initial diagnosis and remained so during the disease development. Unfortunately, 
no follow-up samples from DNMT3A mutation positive patients were available.  
 
5.3 Analysis of the DNMT3A detection tests in comparison to others: 
The following subchapter will discuss the strengths and weaknesses of the present study in 
comparison to other DNMT3A mutation detection methods as well as to similar MRD tests 
screening for other recurrent genetic mutations in acute myeloid leukaemia or other 
haematological diseases. The great majority of studies analysing DNMT3A mutations use 
sequencing technologies as the detection method by which the genetic alteration was first 
identified. The DNMT3A mutation was initially described by two independent research 
groups in 2010: Yamashita and colleagues primarily identified the DNMT3A mutation by 
carrying out large scale array-based genomic resequencing of AML samples (Yamashita Y et 
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al., 2010), whilst Ley et al. performed massively parallel deep sequencing of 281 AML 
patients (Ley et al., 2010). Shortly after this, Yan X-J et al. distinguished the mutation by 
using exome sequencing in acute monocytic leukemia (the M5 subtype of acute myeloid 
leukemia) (Yan X-J et al., 2010). Subsequent studies used direct Sanger sequencing of either 
all coding exons or only exons enriched for genetic alterations within the DNMT3A gene 
(Ostronoff F et al., 2013; Tiacci E et al., 2012; Renneville A et al., 2012; Patel JP et al., 2012).  
However, the ongoing development of these sequencing technologies lacks practical 
applicability and availability in standard diagnostic laboratories and rather advances research 
purposes. Therefore, the differential restriction enzyme screening test provides an 
advantageous rapid and simple analysis for diagnostic laboratories with basic equipment and 
represents a valid method for smaller health care centres with less advanced technologies 
accessible (Brewin JN et al., 2013). 
More recently a comparable endonuclease restriction test to our assay has been developed 
using another specific restriction enzyme with a sensitivity of 0.05% mutant allele frequency 
which is higher than our restriction enzyme test (Berenstein R et al., 2014). This might be due 
to insufficient optimisation in our laboratory, interaction of different buffers or the use of a 
more efficient enzyme.  
Additionally, Mancini M and colleagues (2015) developed a restriction enzyme based RT-
PCR assay to screen for DNMT3A R882 mutations. Compared to our differential restriction 
enzyme test their approach detects R882H, C, S and P alterations while we only confirmed 
our assay for the more common R882H and C mutations. Theoretically, our assay also has 
the ability to detect R882S mutations because this C-to-A transversion results in a serine 
substitution that generates an AluI restriction site, the second endonuclease used in the 
differential restriction enzyme sequence. Though, in our study population no R882S 
substitution was present so that we couldn’t validate the detection of this rare substitution 
(Brewin JN et al., 2013). 
Secondly, Mancini’s research team confirmed the data by capillary electrophoresis while we 
verified our results by Sanger sequencing. In addition, they designed the forward RT-PCR 
primer to generate an additional restriction cut site thus providing an internal cutting control 
whereas the cutting efficiency in the present restriction enzyme test was validated visualising 
two smaller PCR fragments that are generated during complete digestion on an agarose gel. 
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However, those caveats are compensated for the high sensitivity of 5% mutant to wild type 
copy number of our differential restriction enzyme test compared to 10% (Mancini M et al., 
2015).  
The detection of minimal residual disease in acute myeloid leukaemia promises to be a 
powerful parameter for both post therapy monitoring of selected patients for appropriate post 
induction or consolidation therapy along with a potential control during ongoing initial 
treatment to check therapy response but it is still subject to many difficulties such as non 
consistent baseline levels between the different detection methods or the absence of 
longitudinal stability of gene mutations (Paietta E, 2012). In the following different 
paragraphs DNMT3A detection analyses are evaluated and compared to the instant MRD test: 
High resolution melting (HRM) analysis is a technique that measures the melting point of 
double stranded DNA fragments after PCR amplification by measuring fluorescence dye 
levels and is often applied for detection of aberrant sequence variants (Pfaffl MW, 2010).  
In a recent study showing that high DNMT3B (DNA methyltransferase B) levels predict a 
poor prognosis in acute myeloid leukemia DNMT3A mutations in exon 23 were detected by 
RT-PCR and HRM analysis. The method was established using a dilution series of an AML 
sample carrying the R882H mutation resulting in a sensitivity of 2.5% (Hayette S et al., 2012). 
This approach is relatively similar to the present work in terms of development of the 
detection threshold. However, our assay was able to reliably detect DNMT3A R882 mutations 
with a sensitivity of 1%. Nonetheless, the report by Hayette et al. (2012) examines for 
mutations positioned between codon V867 and R891 including codon R882. Admittedly, 
they include 24 codons into the mutational analysis while the present methodology focuses 
only on codon R882 where indeed around 60% of all DNMT3A mutations are found (Ley TJ 
et al., 2010; Yamashita et al., 2011; Renneville A et al., 2012). In conclusion, our assay offers 
a higher sensitivity with a focus on the most frequently altered codon as opposed to a lower 
sensitivity analysis of a larger sequence.  
Further HRM tests include a study by Singh RR et al. (2012) who achieved lower sensitivities 
for the DNMT3A mutation (for exon 8 and 10 within the PWWP domain: 7.2%, and 6.8% of 
cells respectively, for exon 15 within the ADD (ATM-DNMT3A-DNMT3L) zinc finger 
domain 6.4% and finally for exon 18 and 23 within the catalytic domain 8.4% and 6.7% 
respectively. Again this work has the advantage of examining several loci. Another report 
observed the occurrence of DNMT3A mutations in Chinese patients and achieved HRM 
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analysis sensitivity for codon R882 of 2% which was shown to be much more sensitive than 
direct DNA sequencing with 10% sensitivity (Lin J et al., 2011). 
One further, more up-to-date HRM assay by Gorniak P et al. (2015) analysed 67 AML 
samples, among those 12 containing the DNMT3A R882 mutation, with a detection limit of 
10% mutant to wild type DNA. They defined the detection threshold by creating a dilution 
series of a plasmid encompassing the DNMT3A R882 codon in concentrations of 100%, 50%, 
25%, 10%, 5%, 1% and 0%. However, our assay performs better in terms of sensitivity levels 
as the present test repeatedly generated results at a sensitivity level of 1% mutant to wild type, 
0.5% mutant allele frequency respectively (Bisling KE et al., 2013). 
In addition, denaturing high-performance liquid chromatography is widely used to detect 
gene mutations based on the physicochemical difference between homoduplexes (PCR 
amplicons whose DNA strands are completely complementary) and heteroduplexes (PCR 
amplicons with base changes in one DNA strand as a result of a heterozygous mutation) as 
measured by reversed-phase chromatography after partial denaturation (Kosaki K et al., 
2005). This high-capacity and low-cost method has been used to identify DNMT3A mutations 
and allowed their detection with a sensitivity of 5% screening all coding exons of the 
DNMT3A gene in paediatric AML cases and adults younger than 60 years respectively (Liang 
D-C et al., 2013; Ribeiro AFT et al., 2012). In comparison to the present DNMT3A detection 
method the aforementioned assays are able to screen for DNMT3A mutation with a greater 
sensitivity than Sanger sequencing but not more sensitive than the hereby presented 
methodology.  
More importantly, none of the above discussed methods has the capability to quantify the 
DNMT3A mutations in relation to the total number of leukaemic cells.  
A mutation quantification test was recently developed to detect and monitor BRAFV600E 
mutations in hairy cell leukaemia with the purpose of diagnosis and follow-up of affected 
patients (Schnittger S et al., 2012). This assay is based on real-time PCR measurement of the 
expression changes between BRAFV600E mutant to wild type DNA and was established from 
dilution series of a plasmid containing the mutation. In further detail, the sensitivity reaches 
10
-4
 – 10
-5
 which is at least 10 times more precise than the sensitivity for the DNMT3A 
mutation reached in our test (10
-2
 – 10
-3
) and is probably due to higher qPCR efficiencies of 
1.93 to 1.96 compared to 1.85 to 1.79 (as described in 4.2.2.). An additional strength of the 
afore-mentioned test is the external validation of variant patients as assessed by the newly 
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developed test by multiparameter flow cytometry (MFC) and deep-sequencing instead of 
verification by Sanger sequencing as performed in our study.  
 
Lately, PCR technologies determining DNMT3A mutations have significantly improved: 
Mancini M et al., (2015) established a quantification test based on peptide nucleic acid (PNA) 
real-time quantitative PCR which uses artificially synthesised DNA elements that are 
characterised by neutral electrical qualities and therefore obtain stronger interactions between 
DNA strand and PNA probe. As exclusively wild type DNMT3A sequence is linked to the 
PNA probe PCR amplification cannot continue and a different fluorescent signal is registered 
for mutant and WT DNA sequence. As discussed in 5.2.3 our qPCR test uses an amplicon 
inside the DNMT3A gene as a loading control whereas Mancini and colleagues use ABL1 
gene amplification because their quantification methodology is independent of the 
endonuclease study design. In contrast to these differences, the herein presented detection 
method as well as Mancini and colleagues’ work achieves similar sensitivity levels of about 
10
-4
. 
Moreover, another research group set up a bead-based bridged-nucleic acids (BNA) assay 
using oligonucleotide probes with improved hybridisation capability to DNA strands that are 
coupled with fluorescently labelled microbeads. This test features quantitative detection of 
DNMT3A R882C, H, R and S mutations with a sensitivity of 2.5% for the different mutant 
alleles and was validated on dilutions of mutant and wild type plasmid (Shivarov V et al., 
2014; Biosynthesis User Information). Again, this test includes R882R and S mutations in the 
detection profile but fails to reach our sensitivity level of less than 1% of total cells. 
 
One step further towards absolute quantification of the DNMT3A R882H mutation provides a 
study undertaking allele-specific PCR with a blocking reagent (ASB-PCR). In the 
experiments, a plasmid containing the R882H defect is used and enables us to differentiate 
1% R882H positive DNA. Aside from a good sensitivity level of 10
-3
 the test offers exact 
knowledge of the DNMT3A R882H mutational load at different MRD disease stages of AML 
(Berenstein R et al., 2015). 
 
Similarly, Xu L et al. (2013) developed conventional and real-time allele-specific PCR assays 
for detection and quantification of the somatic mutation MYD88 L265P in patients with 
Waldenström’s macroglobulinemia, IgM monoclonal gammopathy and other B-cell 
lymphoproliferative diseases. The conventional PCR test had a sensitivity of 0.1% of mutant 
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allele frequency while the real-time PCR assay could identify MYD88 mutant alleles down to 
a sensitivity of 0.08%. The mutant allele amount was calculated by the ΔΔCt method using 
values for mutant and reference PCR amplicons (Xu L et al., 2013; Schmittgen TD & Livak 
KJ, 2008). Compared to the herewith described DNMT3A detection assays, the sensitivity 
levels of both the real-time and the conventional PCR detection approaches allow very 
precise detection of the corresponding mutation. The validation of results by Sanger 
sequencing was carried out similarly in both projects.  
When analysing the MRD monitoring of NPM1 mutations in acute myeloid leukaemia an 
exemplary study performed by the German-Austrian Acute Myeloid Leukemia Study Group 
(Krönke J et al., 2011) using RNA based real-time quantitative PCR showed maximum 
sensitivity levels of 10
-5
-10
-6
 for the analysed mutation types. The advantages of this study 
are that the established method examines several types of the mutation as well as the high 
sensitivity and specificity. 
In conclusion, our MRD detection assay has a higher sensitivity to screen for DNMT3A R882 
mutations than most other available DNMT3A tests but on the other hand it only focuses on 
one mutational hotspot and doesn’t analyse additional loci. The DNMT3A mutation seems to 
be more difficult to detect than the MYD88, NPM1, and BRAFV600E mutations in 
comparable real-time PCR tests in other haematological illnesses as the maximum 
sensitivities of most of these tests were better. 
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5.4 Conclusions about the significance of the study: 
5.4.1 Significance as a clinical test: 
The differential restriction enzyme test provides a practical and fast approach to detect the 
presence of DNMT3A R882 mutations and also offers some evidence about the subtype of 
R882 mutation. Due to the simplicity and rapidity of the assay it could help the clinician 
reach a timely decision on treatment options as patients with DNMT3A mutations might 
benefit from enhanced chemotherapy regimens (Brewin JN et al., 2012). Therefore, it is 
probably of greater benefit in a small laboratory with limited resources than a laboratory with 
access to deep sequencing techniques. Besides, tests based on conventional PCR need less 
DNA than whole genome- or Sanger sequencing so that this test represents an option for very 
small and precious samples sizes as well (Xu L et al., 2013).  
The quantitative test provides a method for detection of DNMT3A R882 mutations which is 
more sensitive than Sanger sequencing as well as less time-consuming and cost intensive than 
deep- and whole-genome sequencing techniques. This assay provides information on 
prognosis, treatment decisions and minimal residual disease monitoring in AML patients. 
The combination of both tests gives the opportunity to screen patients that are deemed as 
low-risk for the DNMT3A mutation with the basic restriction enzyme method and those that 
are more likely to carry the DNMT3A mutation with a more sensitive analysis using the 
quantification test. 
As recent findings consider DNMT3A mutations to be a founding clone in AML evolution 
and remain in subclinical stages for a long time, management of minimal residual disease 
could be modified to screen not only post-therapy blasts but also pre-leukaemic stem cells 
(Shlush LI et al., 2014; Genovese G et al., 2014). However, further research on the impact of 
DNMT3A on the probability of developing AML is needed before MRD detection could be 
offered to individuals harbouring the DNMT3A mutation prior to outbreak of overt AML. 
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5.4.2 Indications about DNMT3A during clonal evolution in AML:  
A recent study by Ding L et al. (2012) analysed the clonal evolution in relapsed acute 
myeloid leukaemia by whole-genome sequencing of primary tumour and relapsed genomes 
of eight AML patients. The comparison of relapse-specific versus primary tumour mutations 
evolved into the following models of clonal evolution during AML disease development: The 
first pattern was based on a founding clone in the primary tumour which obtained mutations 
and developed into the relapsed clone. The second pattern was that a subclone of the 
founding clone sustained initial therapy, acquired additional mutations and accumulated at 
relapse. DNMT3A mutations were found at high variant allele frequencies in two out of eight 
patients indicating that the mutation was part of all leukaemic cells in those samples and 
probably also present in the founding clone. Under the assumption that the mutations were 
heterozygous, Ding L and colleagues quantified the founding clone and subsequent minor 
clones as 93.72% (which is commensurate with the malignant cellular content of the sample), 
53.12%, 29.04% and 5.10% at first diagnosis while the subclone comprising 5.10% 
developed into the major clone at relapse. As the development of AML is thought to be 
mainly the result of accumulation of multiple mutations in genes affecting differentiation, 
proliferation/cell death and epigenome regulators (Jan M & Majeti R, 2013), DNMT3A 
mutations would then randomly appear during the disease process and therefore derive as 
major or founding and minor clones. However, the present levels of the DNMT3A mutation in 
this project show that of the 22 patient samples 2 major clones (97.6% and 71.1%) but no 
minor clones were present. This clonal pattern suggests that DNMT3A R882 mutations are 
initiating events in AML and contribute to a founding clone. On these grounds, our data 
seems to confirm the work of Welch JS et al. (2012) who used whole-genome sequencing to 
analyse the genomes of M3-AML patients with PML-RARA translocation as a known 
initiating event versus those of normal karyotype M1-AML and the exomes of HSPC 
(haematological stem/progenitor cells) from healthy people. Their findings suggest that the 
majority of mutations observed in AML are haphazard occurrences in HSPCs that were 
accumulated in the background (increasingly more frequent with age) until only a few 
cooperating mutations suffice to create the founding clone. DNMT3A was shown to be 
significantly more often recurrently mutated in M1 AML cases and therefore deemed rather 
as an initiating than a cooperating event. 
It was also reported that mutations in AML affecting epigenetic regulators like DNMT3A 
were mutually exclusive of the presence of transcription-factor fusions that are classically 
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characterised as class II mutations. This acts as indirect evidence supporting the hypothesis 
that DNMT3A is a driver mutation (Kihara R et al., 2014). 
An analysis of clonal haematopoiesis in aplastic anaemia also corroborates this hypothesis, as 
DNMT3A-mutated clones seemed to increase in size over time and arise in AML (Yoshizato 
T et al., 2015). 
 
5.5 Future research: 
Most of the future work necessary to improve both DNMT3A detection tests is already 
mentioned in each section discussing the strengths and limitations of the assays (chapter 5.2.). 
In contrast to the evaluation of the advantages and disadvantages, the following paragraph 
will highlight two main principles that are required in respect of future research. Firstly, 
further studies would involve an increase in the analysed sample size so that more mutant 
samples can be distinguished and quantified. This is crucial and would considerably validate 
the tests because the chance of coincidental results is diminished and it is easier to deduce 
general rules from greater data sets. 
Secondly, the examination of longitudinal samples and a related analysis of potential changes 
in DNMT3A mutation frequency would give an important example of how the quantification 
test can be applied as a minimal residual disease test. 
Above that, despite the high prognostic impact of epigenetic mutations especially that of 
DNMT3A, single mutation detection tests require revision with regard to their clinical 
suitability. As AML is such a heterogeneous and complex disease critical review of single-
reaction qPCR versus multiplexing of several gene loci in one experiment is essential.  
Evidently, current next-generation sequencing approaches identifying DNMT3A mutations 
and other genetic lesions in AML are progressing and will become more broadly available 
and cost-efficient (Shen T et al., 2015).  
At present, numerous different next-generation sequencing technologies are advancing: To 
name just a few examples, target-enrichment methods concentrate on specific tumorigenic 
regions thus reducing costs and material - post-analytic bioinformatics and DNA input 
respectively (Bolli N et al., 2015). Another technique represents microdroplet PCR deep 
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sequencing data allowing simultaneous amplification of several mutational objectives (Cheng 
DT et al., 2014).  
Notably, Luthra R et al. (2014) already accomplished the sequencing of multiple genes 
(among those DNMT3A) within 72h turnaround time, diminished DNA input and with a high 
concordance between two NGS platforms as well as direct Sanger sequencing.  
Nonetheless, further experiments addressing the clinical practicality and applicability of 
sequencing techniques of AML causing mutations will provide substantial and demanding 
tasks for the future.  
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VI. Summary 
Acute myeloid leukaemia is a molecularly heterogeneous clonal disorder that has 
traditionally been stratified in three risk groups to predict patients’ outcome. Recent studies 
suggest that this traditional risk classification requires re-evaluation as numerous somatic 
genetic alterations in epigenetic regulators with effects on the clinical outcome of AML 
patients have been detected. Mutations in the gene de novo methyltransferase 3 A (DNMT3A) 
are one of the most frequent aberrant epigenetic changes in this malignancy comprising 15-
25% of all AML cases and up to 36% in cytogenetically normal AML. As event-free and 
overall-free survival is significantly worse amongst patients harbouring the DNMT3A 
mutation compared to those with DNMT3A wild type AML, different detection methods have 
been developed. However, all tests published up to date have certain limitations regarding the 
level of sensitivity or practicability in a standard diagnostic laboratory. Therefore, we sought 
to develop firstly a rapid screening test in order to identify DNMT3A mutant patients prior to 
treatment and secondly to establish a highly sensitive quantification method to assay for 
DNMT3A mutant minimal residual disease to prevent relapse. Both assays focus on codon 
882 within the DNMT3A gene because more than 60% of all DNMT3A mutations occur at 
this locus.  
The screening test is based on analysis of an aberrant restriction enzyme digestion pattern of 
preliminarily PCR amplified fragments allowing the detection of the DNMT3A R882 
mutation as well as the differentiation between the R882H, R882C and R882S mutation 
subtypes. The sensitivity of the restriction enzyme assay was confirmed by semi-quantitative 
PCR experiments of a dilution series of the DNMT3A R882C mutant cell line OCI/AML-3 in 
wild type cell line KG-1 leading to a test sensitivity of 5% mutant to wild type copy number. 
The quantification method consists of three steps: First, genomic DNA from the OCI/AML-3 
cell line, the KG-1 cell line or from patients’ samples is isolated and the region encompassing 
the DNMT3A R882 codon is amplified by PCR. Then, this PCR product is digested by a 
restriction enzyme sensitive for the DNMT3A R882 mutation and the processed fragments are 
re-amplified by quantitative PCR producing three independent fragments within the 
DNMT3A gene. The quantification of the mutation is calculated as the relative ratio of the 
abundance of an upstream amplicon representing a loading control and a fragment 
encompassing the R882 codon. The third amplicon serves as a control for complete 
restriction enzyme digestion.  
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The sensitivity of the quantification assay was determined by calibration curve experiments 
with the lowest detectable level of 0.78% DNMT3A R882C mutant in wild type DNA leading 
to a test sensitivity of less than 1% of total cells or 0.5% of allele frequency. The 
reproducibility of the quantification method for each observation was verified by a separate 
experimental run confirming that there was no statistically relevant difference between the 
original and the repeated data set. 
After reproducing reliable results on the cell lines, we analysed 42 AML samples and 6 other 
haematological samples (mostly MDS and MPN) using the differential restriction enzyme 
test and the quantification method. Out of the 42 AML samples, 2 DNMT3A R882H 
mutations and one R882C mutation were identified. The presence of the DNMT3A mutation 
was excluded in all other 39 AML samples and the 6 MDS/MPN samples. The two R882H 
mutations were quantified as 97.6 ±	 1.9 % and 71.1 ± 3.3 % respectively. The mutational 
status of all patients’ samples was validated by external Sanger sequencing. 
Finally, the clinical outcome of the patients positive for the DNMT3A R882 mutation was 
compared to those with DNMT3A wild type but no statistically significant differences were 
assessed. However, we observed a moderate trend towards higher probability of male sex, an 
accumulation of a higher blast count and an increased affiliation to the intermediate risk 
group within the DNMT3A R882 mutant study group. 
In consideration of the aims of this study, we successfully established a screening test for the 
presence of the DNMT3A R882 mutation with following advantages: The rapidity of the 
complete process with a duration of a few hours between a patient’s bone marrow aspiration 
and determination of the mutation status as well as the benefit of the relatively low 
experimental cost and the use of basic laboratorial techniques. On top of that, we succeeded 
to reach a sensitivity of 5% mutant to wild type copy number. Although there were 
limitations regarding the differentiation between the subtypes of the DNMT3A R882 mutation, 
the test offers a facilitation of the risk classification and appropriate choice of treatment in 
situations with an urgent need of a decision based on prognostic risk factors.  
In regard to the quantification method, we succeeded in setting up a highly sensitive detection 
and quantification test to be able to screen for minimal residual disease. While we focused on 
the mutational hotspot codon R882 other research groups developed tests using HRM curve 
analyses and dHPLC that examine up to 24 codons. Nevertheless, none of the afore 
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mentioned studies reached the sensitivity level of 1% mutant to wild type copy number at the 
R882 locus. Furthermore, our quantification technique is less time-consuming and more cost 
saving.  
In conclusion, the differential restriction enzyme test provides the clinician with a practical 
approach to screen for the DNMT3A R882 mutation to evaluate the patient’s prognosis while 
the quantification method could serve as a reliable parameter to verify post treatment 
remission as well as to investigate for minimal residual disease to prevent AML relapse.  
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IX. Zusammenfassung 
Akute myeloische Leukämie (AML) ist eine heterogene Erkrankungsgruppe klonaler 
Neoplasien, die traditionell in drei Risikogruppen eingeteilt wird. Neuere Studienergebnisse 
verdeutlichen die Notwendigkeit einer Re-Evaluation dieser Einteilung, da insbesondere 
Mutationen in epigenetischen Regulatoren und deren klinischer Einfluss bisher nicht 
berücksichtigt werden. Eine der häufigsten epigenetischen Veränderungen bei akuter 
myeloischer Leukämie ist eine Mutation im Gen der De Novo Methyltransferase 3A 
(DNMT3A), die bei 15-25% sämtlicher Fälle von AML und bei bis zu 36% der AML 
Erkrankungen mit unauffälliger Zytogenetik vorkommt. Aufgrund der Verkürzung der 
rezidivfreien Lebensspanne sowie der Gesamtüberlebenszeit der Patienten, die diese 
Mutation aufweisen, wurden unterschiedliche Detektionsmethoden entwickelt. Dabei 
bestehen bislang jedoch deutliche Einschränkungen, beispielsweise durch niedrige 
Sensitivitätsraten oder eingeschränkte Praktikabilität in diagnostischen Laboren mit 
standardisierter Ausrüstung. 
 
Darauf basierend gab es folgende Zielsetzung für diese Studie: Erstens die Entwicklung eines 
Screeningtests, der die Präsenz der DNMT3A Mutation vor Behandlungsbeginn überprüft, 
sowie zweitens eine hochsensitive Quantifikationsmethode, mithilfe derer minimale residuale 
DNMT3A Mutationen, beispielsweise zum Zeitpunkt der Remission, identifiziert werden 
können, um Rezidive frühzeitig zu erkennen. Bei beiden Ansätzen liegt der Fokus auf dem 
Codon 882, da mehr als 60% der DNMT3A Mutationen die Aminosäure Arginin in dieser 
Position alterieren. 
Der Screening Test baut auf einer Analyse von zuvor durch PCR amplifizierten DNA 
Fragmenten und deren voneinander abweichenden Restriktionsenzymmustern auf, wodurch 
sowohl die Identifikation von DNMT3A R882 Mutationen als auch die Unterscheidung 
zwischen R882H, R882C und R882S Subtypen ermöglicht wird. Die Sensitivität des Tests 
wurde durch Verdünnungsreihen der DNMT3A positiven Zellreihe OCI/AML-3 und der für 
dieses Gen als Wildtyp vorliegenden Zelllinie KG-1 bestimmt und lag bei 5%. 
 
Zur Quantifizierung der Mutation werden drei Schritte benötigt: Zuerst wird die genomische 
DNA einer Zelllinie oder einer Patientenprobe isoliert und die Zielregion, die das R882 
Codon beinhaltet, mittels PCR amplifiziert. Dann wird das PCR Produkt durch 
Restriktionsenzyme geteilt. Die dabei entstehenden drei unabhängigen Amplikons werden 
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wiederum durch quantitative PCR vervielfältigt. Die Quantifizierung erfolgt durch den 
relativen Anteil des durch die Mutation alterierten R882 Amplikons in Bezug zu einer 
„Loading Control“, die im gleichen Gen liegt, aber durch das Restriktionsenzym nicht 
geschnitten wird. Das dritte Amplikon dient als Kontrolle für die Effizienz des 
Restriktionsenzyms („Digestion Control“) und enthält eine weitere Zielstruktur des Enzyms. 
Die Sensitivität der Quantifikationsmethode wurde durch Kalibrierungsexperimente bestimmt, 
welche die niedrigste detektierbare Rate von DNMT3A mutierten Allelen zu Wildtyp Allelen 
von 0,78% zeigte. Die Reliabilität der Quantifikationsmethode wurde durch separate 
Wiederholungen der Experimente und statistischen Vergleich der erhobenen Daten verifiziert.  
Nachdem die Experimente basierend auf den Zelllinien reliabel reproduziert werden konnten, 
wurden 42 AML und 6 weitere hämatologische Proben (vorrangig aus dem 
myelodysplastischen und myeloproliferativen Formenkreis) mit beiden Ansätzen untersucht. 
Unter den 42 AML Proben lagen 2 DNMT3A R882H Mutationen und eine R882C Mutation 
vor. Bei den übrigen 39 AML Fällen und den 6 weiteren Proben konnte das Vorkommen der 
DNMT3A Mutation, auch in geringer Anzahl, ausgeschlossen werden. Die zwei R882H 
positiven Befunde wurden als jeweils 97.6 ±	 1.9 % und 71.1 ± 3.3 % quantifiziert. Der 
Mutationsstatus sämtlicher Proben wurde durch Sanger Sequencing validiert. 
In der Folge wurden die klinischen Charakteristika der DNMT3A Träger analysiert. Dabei 
wurden unter den DNMT3A Trägern vermehrt männliche Probanden gefunden, eine höhere 
Anzahl von Blasten in der Knochenmarkbiopsie sowie ein vermehrtes Auftreten einer 
Eingruppierung in der „intermediate risk“ Gruppe beobachtet; dies allerdings ohne 
statistische Signifikanz.  
Durch die erfolgreiche Entwicklung des Screeningtests konnten mehrere Vorteile erarbeitet 
werden: Die schnelle Erfassung der Prognose eines Patienten mit lediglich 4-5 Stunden 
Zeitbedarf zwischen Blutentnahme bzw. Knochenmarkbiopsie und der Diagnose des 
DNMT3A Genstatus, wodurch eine frühzeitige Risikostratifizierung eines Patienten und eine 
stärker individualisierte Wahl des Therapieregimes ermöglicht wird. Dazu kommt der relativ 
geringe Kostenaufwand sowie der Gebrauch von weit verbreiteten und standardisierten 
Labortechniken.  
Mit der Quantifizierungsmethode wurde ein hoch sensitiver Ansatz zur Detektion von 
minimalen residualen Leukämiezellen etabliert, der eine reliable Möglichkeit zur 
Früherkennung der häufigsten Ursache für Rezidive bietet. 
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